Company Overview

Business Model: Johnson & Johnson and its subsidiaries (the Company) are engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field, primarily focused on human health and well-being. The Company operates globally through two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment distributes prescription medicines directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals. The MedTech segment distributes products to wholesalers, hospitals, and retailers, predominantly for use by physicians, nurses, hospitals, eye care professionals, and clinics.

Market Position: The Company competes globally across all product lines based on cost-effectiveness, technological innovations, intellectual property rights, product performance, pricing, and reimbursement. It emphasizes the development of new and innovative products and the protection of its intellectual property. New products introduced within the past five years accounted for approximately 25% of 2024 sales. The Company's largest product, collectively DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), accounted for approximately 13.1% of total revenues for fiscal 2024. STELARA (ustekinumab) accounted for approximately 11.7% of total revenues for fiscal 2024.

Recent Strategic Developments:

• Kenvue Divestiture: Completed the disposition of Kenvue Inc. through an initial public offering (IPO) in May 2023 and a subsequent exchange offer in August 2023, fully divesting its remaining stake via a debt-for-equity exchange in May 2024. The Consumer Health business results are now reflected as discontinued operations.
• Acquisitions:
  • Shockwave Medical Inc.: Acquired in May 2024 for approximately $15.1 billion (net of cash acquired) to enhance the MedTech segment's Cardiovascular portfolio with intravascular lithotripsy technology.
  • Ambrx Biopharma, Inc.: Acquired in March 2024 for approximately $1.8 billion (net of cash acquired) to advance the Innovative Medicine segment's oncology pipeline with antibody drug conjugates (ADCs).
  • Proteologix, Inc.: Acquired in June 2024 for approximately $0.8 billion (net of cash acquired) to bolster the Innovative Medicine segment's immunology portfolio with bispecific antibodies.
  • V-Wave Ltd.: Acquired in October 2024 for an upfront payment of $0.6 billion, with potential for additional milestones, to develop heart failure treatments within the MedTech segment.
  • Yellow Jersey (Numab Therapeutics AG subsidiary): Acquired global rights to NM26, a bispecific antibody for atopic dermatitis, for approximately $1.25 billion in July 2024.
• Pipeline Advancement: Advanced its pipeline with several regulatory submissions and approvals for new drugs and additional indications for existing drugs in 2024 across both segments, including CARVYKTI, DARZALEX, ERLEADA, OPSYNVI, RYBREVANT, and TREMFYA.
• Restructuring Initiatives: Completed a restructuring of its Innovative Medicine R&D investment in Q4 2024 to focus on promising medicines, exiting certain programs in infectious diseases and vaccines. Initiated a restructuring program in its MedTech Orthopaedics franchise in 2023 to streamline operations by exiting certain markets, product lines, and distribution network arrangements, expected to be completed by the end of fiscal year 2025.

Geographic Footprint: The Company conducts business in virtually all countries worldwide. In fiscal 2024, approximately 43% of total sales occurred outside the U.S., with 23% in Europe, 5% in the Western Hemisphere (excluding the U.S.), and 15% in the Asia-Pacific and Africa region.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 69.1% (2024)
• Operating Margin: 13.6% (2024)
• Net Margin: 15.8% (2024)

Investment in Growth:

• R&D Expenditure: $17.2 billion (19.4% of revenue)
• Capital Expenditures: $4.4 billion
• Strategic Investments: Acquisitions, net of cash acquired, totaled $15.1 billion in 2024, primarily for Shockwave Medical Inc., Ambrx Biopharma, Inc., and Proteologix, Inc. Acquired in-process research and development assets totaled $1.8 billion in 2024, including V-Wave Ltd. and global rights to the NM26 bispecific antibody.

Business Segment Analysis

Innovative Medicine

Financial Performance:

• Revenue: $57.0 billion (+4.0% YoY, +5.7% operational growth)
• Operating Margin: 33.2%
• Key Growth Drivers: Strong performance in Oncology (DARZALEX, ERLEADA, CARVYKTI, TECVAYLI, TALVEY, RYBREVANT) and Pulmonary Hypertension (OPSUMIT, UPTRAVI, OPSYNVI) due to market growth, share gains, capacity expansion, and new product launches. Partially offset by declines in Immunology (STELARA due to European biosimilar entrants, REMICADE due to biosimilar competition) and Infectious Diseases (primarily due to COVID-19 vaccine revenue decline).
• Investment in Growth: Increased R&D expenditure, including $1.25 billion for global rights to the NM26 bispecific antibody.
• Other Segment Items: Included $0.3 billion from monetization of royalty rights and lower COVID-19 Vaccine related exit costs, partially offset by litigation expense ($0.4 billion primarily related to Risperdal Gynecomastia) and an intangible asset impairment charge of $0.2 billion for the M710 (biosimilar) asset.

Product Portfolio:

• Immunology: REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab).
• Infectious Diseases: EDURANT (rilpivirine), PREZISTA (darunavir), PREZCOBIX/REZOLSTA (darunavir/cobicistat), SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide).
• Neuroscience: CONCERTA (methylphenidate HCl), INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate), SPRAVATO (Esketamine).
• Oncology: CARVYKTI (ciltacabtagene autoleucel), ZYTIGA (abiraterone acetate), ERLEADA (apalutamide), IMBRUVICA (ibrutinib), DARZALEX (daratumumab), DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs), RYBREVANT (amivantamab).
• Cardiovascular and Metabolism: XARELTO (rivaroxaban).
• Pulmonary Hypertension: OPSUMIT (macitentan), UPTRAVI (selexipag), OPSYNVI (macitentan/tadalafil).
• New product launches/major updates in 2024 include BALVERSA (erdafitinib), CARVYKTI, DARZALEX, EDURANT, OPSYNVI, RYBREVANT, and TREMFYA for various new indications or formulations.

Market Dynamics:

• Faces biosimilar competition for key products like STELARA (expected continued launches in Europe and U.S. in 2025) and REMICADE (continued competition).
• Oncology segment benefits from continued share gains and market growth.
• Neuroscience growth partially offset by declines in older products.

MedTech

Financial Performance:

• Revenue: $31.9 billion (+4.8% YoY, +6.2% operational growth)
• Operating Margin: 11.7%
• Key Growth Drivers: Strong growth in Cardiovascular (Electrophysiology, Abiomed, Shockwave) due to global procedure growth, new product performance, and commercial execution. Orthopaedics saw growth in Hips and Knees (ATTUNE portfolio, VELYS Robotic assisted solution) and Trauma (recently launched products). Partially offset by declines in Surgery (China volume-based procurement, competitive pressures in Energy and Endocutters) and Spine, Sports & Other (competitive pressures, China volume-based procurement).
• Investment in Growth: Acquisition and integration related costs of $1.0 billion primarily related to the Shockwave acquisition, and acquired in-process R&D expense of $0.5 billion from the V-Wave acquisition.
• Other Segment Items: Included a gain of $0.2 billion related to the Acclarent divestiture.

Product Portfolio:

• Cardiovascular: Electrophysiology products, heart recovery portfolio (Abiomed, including Impella 5.5 and Impella RP), circulatory restoration products (Shockwave for calcified coronary artery disease and peripheral artery disease), neurovascular care for stroke.
• Orthopaedics: Products and enabling technologies for hips, knees, trauma, spine, sports, and others (e.g., ATTUNE portfolio, VELYS Robotic assisted solution).
• Surgery: Advanced and general surgery technologies, breast aesthetics and reconstruction solutions (Mentor).
• Vision: ACUVUE brand contact lenses and TECNIS intraocular lenses for cataract surgery.

Market Dynamics:

• Cardiovascular segment significantly impacted by the acquisition of Shockwave Medical Inc. in May 2024.
• Faces competitive pressures and volume-based procurement in China across several product lines (Surgery, Spine, Sports & Other, Vision Surgical).
• Orthopaedics experienced a one-time revenue recognition timing change in the U.S. positively impacting growth, but also near-term disruption from restructuring.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $2.4 billion (15.2 million shares) in 2024, primarily as part of a systematic plan to meet compensation program needs.
• Dividend Payments: $11.8 billion ($4.91 per share) in 2024.
• Dividend Yield: Not explicitly stated, but the Company increased its dividend in 2024 for the 62nd consecutive year.
• Future Capital Return Commitments: A regular cash dividend of $1.24 per share was declared on January 2, 2025, payable on March 4, 2025.

Balance Sheet Position:

• Cash and Equivalents: $24.1 billion (as of December 29, 2024)
• Total Debt: $36.6 billion (as of December 29, 2024)
• Net Cash Position: $(12.1) billion (net debt position)
• Credit Rating: Maintains investment grade credit ratings (specific ratings not disclosed).
• Debt Maturity Profile: Aggregate maturities of long-term debt obligations are $1.7 billion in 2025, $2.0 billion in 2026, $2.4 billion in 2027, $2.3 billion in 2028, $1.4 billion in 2029, and $22.5 billion after 2029.

Cash Flow Generation:

• Operating Cash Flow: $24.3 billion
• Free Cash Flow: $19.8 billion (Operating Cash Flow of $24.3 billion minus Capital Expenditures of $4.4 billion)
• Cash Conversion Metrics: Accounts receivable and inventories increased by $1.5 billion, while accounts payable and accrued liabilities increased by $1.6 billion.

Operational Excellence

Production & Service Model: The Company's subsidiaries operate 64 manufacturing facilities worldwide, occupying approximately 9.6 million square feet. The Company generally seeks to own its manufacturing facilities, though some are leased, particularly in non-U.S. locations. It also engages contract manufacturers. The Company is committed to maintaining all properties in good operating condition.

Supply Chain Architecture: The Company relies on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements. Raw materials essential to the business are generally readily available from multiple sources. Key Suppliers & Partners:

• Wholesalers: Three wholesalers distributed products for both segments, representing approximately 20.5%, 15.6%, and 12.3% of total gross revenues in 2024.
• Collaborative Partners: XARELTO (co-developed with Bayer HealthCare AG), IMBRUVICA (developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company), CARVYKTI (licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited), DARZALEX (licensed from Genmab A/S).

Facility Network:

• Manufacturing: 64 facilities globally (23 in U.S., 21 in Europe, 7 in Western Hemisphere excluding U.S., 13 in Africa, Asia and Pacific). Innovative Medicine uses 18 facilities (4 U.S., 14 international), MedTech uses 46 facilities (19 U.S., 27 international).
• Research & Development: Significant investments in R&D are made to discover, test, and develop new products and improve existing ones.
• Distribution: Numerous office and warehouse facilities are maintained worldwide.

Operational Metrics: Not explicitly detailed beyond facility counts and R&D expenditure.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Medicines in the Innovative Medicine segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
• Channel Partners: MedTech products are distributed to wholesalers, hospitals, and retailers.
• Digital Platforms: Not explicitly detailed in terms of sales channels, but the Company uses its websites for communication with investors and the public.

Customer Portfolio: Enterprise Customers: Products are used predominantly in professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Customer Concentration: Three wholesalers represented approximately 20.5%, 15.6%, and 12.3% of total gross revenues in 2024. Geographic Revenue Distribution:

• United States: 56.6% of total revenue ($50.3 billion)
• Europe: 22.8% of total revenue ($20.2 billion)
• Western Hemisphere, excluding U.S.: 5.3% of total revenue ($4.7 billion)
• Asia-Pacific, Africa: 15.3% of total revenue ($13.6 billion)

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The Company operates in highly competitive product markets globally, characterized by substantial investments in continuing research and development. The healthcare industry faces increasing scrutiny from government agencies and legislative bodies regarding costs, pricing, and market practices. Trends toward healthcare cost containment, consolidation among healthcare providers, managed care, and government as primary payors are significant. Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: The Company competes with companies of all sizes, both locally and globally. Specific competitors are not explicitly named in a comprehensive list, but the filing mentions:

• Generic/Biosimilar Manufacturers: Companies challenging patents for products like REMICADE and STELARA.
• Pharmacyclics LLC, an AbbVie company: Co-markets IMBRUVICA.
• Bayer HealthCare AG: Co-developed XARELTO.
• Legend Biotech USA Inc. and Legend Biotech Ireland Limited: Collaborates on CARVYKTI.
• Genmab A/S: Licenses DARZALEX.
• Maquet Cardiovascular LLC: Involved in patent litigation with Abiomed.
• C.R. Bard, Inc.: Mentioned in context of polypropylene mesh device litigation.
• Sandoz Inc., Hikma Pharmaceuticals Inc. USA, Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd.: Named as defendants in SPRAVATO patent infringement lawsuits.
• Jamp Pharma Corporation and Apotex Inc.: Named as defendants in INVOKANA patent infringement lawsuits.

Emerging Competitive Threats: New entrants, disruptive technologies (including AI), and increasingly aggressive challenges to intellectual property rights by competitors seeking to launch generic/biosimilar products.

Competitive Response Strategy: Substantial investments in continuing research, protecting intellectual property, securing rights to acquisitions, collaborations, and licensing agreements, and introducing new products or technological advances.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Healthcare Cost Containment: Pricing pressures from third-party payors (government, private insurance, managed care), consolidation among healthcare providers, and new entrants seeking to reduce costs.
• Government Pricing Pressure: Impact of the Inflation Reduction Act (IRA) on Medicare drug pricing (XARELTO, STELARA, IMBRUVICA selected for negotiation), potential for government-established prices, and rebates for price increases exceeding inflation. Ongoing litigation challenges the IRA's constitutionality.
• Patent Expirations & Biosimilar/Generic Competition: Substantial reduction in sales and market share losses following patent expirations (e.g., STELARA, REMICADE) and introduction of competing products.
• Technology Disruption: Challenges in innovation and development of new products, product and process obsolescence due to competitor advances, and risks associated with evolving AI technologies (obsolescence, unintended consequences, new regulations).
• Customer Concentration: Reliance on three wholesalers for a significant portion of gross revenues (20.5%, 15.6%, 12.3% in 2024).

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Manufacturing Interruptions: Difficulties and delays in manufacturing (internal or third-party) due to regulatory action, quality deviations, labor disputes/shortages, natural disasters, raw material shortages, political unrest, epidemics/pandemics.
• Supplier Dependency: Reliance on third parties for raw materials, components, and products, with risks of failure to meet capacity, quality, or timely delivery, and potential for increased costs.
• Information Technology Systems: Interruptions and breaches of internal or vendor IT systems (cybersecurity threats), potentially leading to reputational, competitive, operational, or financial harm and regulatory action.

Financial & Regulatory Risks

Market & Financial Risks:

• Foreign Currency Exchange: Fluctuations in non-U.S. currencies relative to the U.S. dollar impact revenues and expenses (43% of 2024 sales outside U.S.).
• Inflation and Currency Devaluation: Challenges in maintaining profitability in highly inflationary economies (Argentina, Turkey, Venezuela, Egypt).
• Credit & Liquidity: Weak financial performance or credit rating downgrade could increase borrowing costs and reduce access to capital markets. Regulatory & Compliance Risks:
• Increasing Governmental Regulation: Costly and complex U.S. and foreign laws (e.g., U.S. FDA, EU Medical Devices Regulation, privacy laws, AI regulation) leading to increased testing, documentation, and enforcement.
• Product Efficacy/Safety Concerns: Product withdrawals, recalls, regulatory action, declining sales, reputational damage, and litigation.
• Legal Proceedings: Significant litigation exposure including product liability (talc, ASR Hip, PINNACLE, pelvic mesh, Physiomesh, PROCEED, PROLENE, RISPERDAL, ELMIRON), patent disputes, and government investigations (opioids, anti-competitive behavior, False Claims Act, FCPA).
• Tax Law Changes: Changes in domestic and international tax laws (e.g., OECD Pillar Two Directive) and increased audit scrutiny by tax authorities could impact effective tax rate and liabilities.

Geopolitical & External Risks

Geopolitical Exposure:

• Global Operations Risks: Financial instability in international economies, sovereign risk, governmental controls, restrictive economic policies, unstable international governments and legal systems.
• Trade Relations: Potential changes in export/import laws, trade restrictions, tariffs, and drug reimportation legislation impacting raw material prices, supply chains, and product development.
• Global Tensions and War: Adverse effects on business, results of operations, or financial condition due to global tensions and war (e.g., Russia-Ukraine war, Middle East conflict), leading to foreign currency volatility, decreased demand, supply chain challenges, export controls, and sanctions.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Immunology: Treatments for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, psoriasis.
• Infectious Diseases: HIV/AIDS.
• Neuroscience: Mood disorders, neurodegenerative disorders, schizophrenia, attention deficit hyperactivity disorder, treatment-resistant depression.
• Oncology: Prostate cancer, hematologic malignancies, lung cancer, bladder cancer (including CAR-T cell therapy, bispecific antibodies, androgen receptor inhibitors, BTK inhibitors, CD38-directed cytolytic antibodies, bispecific T-cell engagers, antibody drug conjugates).
• Cardiovascular and Metabolism: Thrombosis, diabetes, macular degeneration, heart rhythm disorders, severe coronary artery disease, AMI cardiogenic shock, calcified coronary artery disease, peripheral artery disease, hemorrhagic and ischemic stroke.
• Pulmonary Hypertension: Pulmonary Arterial Hypertension.
• Investment Level: $17.2 billion invested in R&D in 2024, representing 19.4% of revenue.
• Innovation Pipeline: Actively developing new compounds, strategies, and technologies, including leveraging data science, machine learning, and AI. New products introduced within the past five years accounted for approximately 25% of 2024 sales.

Intellectual Property Portfolio:

• Patent Strategy: Practices obtaining patent protection on products and processes globally, owning or licensing a significant number of patents. Patents related to DARZALEX (expiring in U.S. in 2029, Europe 2031/2032) and DARZALEX FASPRO are material.
• Licensing Programs: Many medicines developed in collaboration with strategic partners or licensed from other companies.
• IP Litigation: Faces patent challenges from third parties (generic/biosimilar companies) seeking to market competing products prior to patent expiration, as well as allegations of infringing third-party IP rights. Significant ongoing litigation for XARELTO, INVEGA SUSTENNA, INVEGA TRINZA, SYMTUZA, ERLEADA, SPRAVATO, INVOKANA, and Impella.

Technology Partnerships:

• Strategic Alliances: Collaborations with companies like Bayer HealthCare AG (XARELTO), Pharmacyclics LLC, an AbbVie company (IMBRUVICA), Legend Biotech USA Inc. and Legend Biotech Ireland Limited (CARVYKTI), and licensing from Genmab A/S (DARZALEX).

Leadership & Governance

Executive Leadership Team

Company Overview

Business Model: Johnson & Johnson and its subsidiaries (the Company) are a global healthcare enterprise focused on human health and well-being. The Company operates through two primary business segments: Innovative Medicine and MedTech. The Innovative Medicine segment is dedicated to the research, development, manufacture, and sale of prescription pharmaceutical products across therapeutic areas such as Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism, and Pulmonary Hypertension, distributed directly to various healthcare entities. The MedTech segment offers a broad portfolio of medical products in categories including Cardiovascular, Orthopaedics, Surgery, and Vision, distributed to wholesalers, hospitals, and retailers for professional use by healthcare providers.

Market Position: The Company maintains a competitive stance across all product lines and geographic markets, driven by continuous investment in research and development, technological innovation, and intellectual property protection. New products launched within the last five years contributed approximately 25% of the Company's 2024 sales, underscoring its focus on innovation. DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) collectively represented approximately 13.1% of total revenues in fiscal 2024, while STELARA (ustekinumab) accounted for approximately 11.7% of total revenues.

Recent Strategic Developments:

• Kenvue Divestiture: The Company completed the full separation of its Consumer Health business, Kenvue Inc., in May 2024 through an initial public offering in May 2023 and a subsequent debt-for-equity exchange of its remaining stake. The historical results of the Consumer Health business are now reported as discontinued operations.
• Strategic Acquisitions: In 2024, the Company made significant acquisitions to bolster its portfolio:
  • Shockwave Medical Inc.: Acquired in May 2024 for approximately $15.1 billion (net of cash acquired) to expand its MedTech Cardiovascular portfolio with intravascular lithotripsy technology.
  • Ambrx Biopharma, Inc.: Acquired in March 2024 for approximately $1.8 billion (net of cash acquired) to enhance the Innovative Medicine Oncology pipeline with next-generation antibody drug conjugates.
  • Proteologix, Inc.: Acquired in June 2024 for approximately $0.8 billion (net of cash acquired) to strengthen the Innovative Medicine Immunology portfolio with bispecific antibodies.
  • V-Wave Ltd.: Acquired in October 2024 for an upfront payment of $0.6 billion, with potential for additional milestones, to develop heart failure treatments within MedTech.
  • Yellow Jersey (Numab Therapeutics AG subsidiary): Acquired global rights to NM26, a bispecific antibody for atopic dermatitis, for approximately $1.25 billion in July 2024.
• Pipeline Advancements: The Company secured several regulatory submissions and approvals in 2024 for new drugs and expanded indications, including CARVYKTI, DARZALEX, ERLEADA, OPSYNVI, RYBREVANT, and TREMFYA.
• Restructuring Initiatives: The Innovative Medicine segment completed a restructuring of its R&D investment in Q4 2024 to prioritize promising medicines, exiting certain infectious diseases and vaccine programs. The MedTech Orthopaedics franchise initiated a restructuring program in 2023 to streamline operations, expected to conclude by the end of fiscal year 2025.

Geographic Footprint: The Company operates globally, with approximately 43% of its 2024 sales generated outside the U.S. Key international markets include Europe (23% of total sales), Asia-Pacific and Africa (15%), and the Western Hemisphere excluding the U.S. (5%).

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 69.1%
• Operating Margin: 13.6%
• Net Margin: 15.8%

Investment in Growth:

• R&D Expenditure: $17,232 million (19.4% of revenue)
• Capital Expenditures: $4,424 million
• Strategic Investments: Acquisitions, net of cash acquired, totaled $15,146 million in 2024. Acquired in-process research and development assets totaled $1,783 million in 2024.

Business Segment Analysis

Innovative Medicine

Financial Performance:

• Revenue: $56,964 million (+4.0% YoY, +5.7% operational growth)
• Operating Margin: 33.2% (Segment income before tax as a percent to segment sales)
• Key Growth Drivers: Strong performance in Oncology, driven by DARZALEX, ERLEADA, CARVYKTI, TECVAYLI, TALVEY, and RYBREVANT, benefiting from continued share gains, market growth, capacity expansion, and manufacturing efficiencies. Pulmonary Hypertension products (OPSUMIT, UPTRAVI, OPSYNVI) also contributed to growth due to market expansion and share gains.
• Key Growth Headwinds: Sales declines in Immunology, particularly STELARA due to European biosimilar entrants and REMICADE due to continued biosimilar competition. Infectious Diseases sales also declined, primarily due to reduced COVID-19 vaccine revenue.
• Other Segment Items: Included $0.3 billion from monetization of royalty rights and lower COVID-19 Vaccine related exit costs ($0.1 billion in 2024 vs. $0.7 billion in 2023). Partially offset by litigation expense of $0.4 billion (primarily Risperdal Gynecomastia) and an intangible asset impairment charge of $0.2 billion for the M710 (biosimilar) asset.

Product Portfolio:

• Immunology: REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab).
• Infectious Diseases: EDURANT (rilpivirine), PREZISTA (darunavir), PREZCOBIX/REZOLSTA (darunavir/cobicistat), SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide).
• Neuroscience: CONCERTA (methylphenidate HCl), INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate), SPRAVATO (Esketamine).
• Oncology: CARVYKTI (ciltacabtagene autoleucel), ZYTIGA (abiraterone acetate), ERLEADA (apalutamide), IMBRUVICA (ibrutinib), DARZALEX (daratumumab), DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs), RYBREVANT (amivantamab).
• Cardiovascular and Metabolism: XARELTO (rivaroxaban).
• Pulmonary Hypertension: OPSUMIT (macitentan), UPTRAVI (selexipag), OPSYNVI (macitentan/tadalafil).
• New product launches or major updates in 2024 include BALVERSA (erdafitinib), CARVYKTI, DARZALEX, EDURANT, OPSYNVI, RYBREVANT, and TREMFYA for various new indications or formulations.

Market Dynamics:

• Faces significant biosimilar competition for STELARA, with continued launches expected in Europe and the United States in 2025. REMICADE also continues to face biosimilar competition.
• Oncology segment benefits from strong market growth and the introduction of new, innovative therapies.
• The Company maintains a policy impacting 340B contract pharmacy transactions to identify inappropriate duplicate discounts and diversion.

MedTech

Financial Performance:

• Revenue: $31,857 million (+4.8% YoY, +6.2% operational growth)
• Operating Margin: 11.7% (Segment income before tax as a percent to segment sales)
• Key Growth Drivers: Cardiovascular franchise, including Shockwave Medical Inc. (acquired May 2024), saw significant growth (21.4% total change, 22.8% operational change), driven by global procedure growth, new product performance, and commercial execution in Electrophysiology and Abiomed. Orthopaedics experienced growth in Hips, Knees (ATTUNE portfolio, VELYS Robotic assisted solution), and Trauma due to portfolio strength, technology penetration, and global procedure growth. Vision Contact Lenses/Other grew due to price actions and strong performance of ACUVUE OASYS 1-Day family.
• Key Growth Headwinds: Surgery sales declined due to China volume-based procurement and competitive pressures in Advanced Surgery (Energy and Endocutters). Spine, Sports & Other declined due to competitive pressures and China volume-based procurement.
• Other Segment Items: Included acquisition and integration related costs of $1.0 billion (primarily Shockwave acquisition) and acquired in-process R&D expense of $0.5 billion from the V-Wave acquisition. Partially offset by a gain of $0.2 billion related to the Acclarent divestiture.

Product Portfolio:

• Cardiovascular: Electrophysiology products, heart recovery portfolio (Abiomed, including Impella 5.5 and Impella RP), circulatory restoration products (Shockwave for calcified coronary artery disease and peripheral artery disease), and neurovascular care for stroke.
• Orthopaedics: Products and enabling technologies for hips, knees, trauma, spine, sports, and others.
• Surgery: Advanced and general surgery technologies, as well as breast aesthetics and reconstruction solutions (Mentor).
• Vision: ACUVUE brand contact lenses and TECNIS intraocular lenses for cataract surgery.

Market Dynamics:

• The Shockwave acquisition significantly expanded the Cardiovascular portfolio.
• Faces competitive pressures and volume-based procurement in China across multiple product categories.
• Orthopaedics restructuring program is underway to streamline operations.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $2,432 million in 2024, representing 15,183 thousand shares, primarily as part of a systematic plan to meet the needs of the Company’s compensation programs.
• Dividend Payments: $11,823 million ($4.91 per share) in 2024.
• Dividend Yield: Not explicitly disclosed.
• Future Capital Return Commitments: The Board of Directors declared a regular cash dividend of $1.24 per share on January 2, 2025, payable on March 4, 2025.

Balance Sheet Position:

• Cash and Equivalents: $24,105 million (as of December 29, 2024)
• Total Debt: $36,634 million (Loans and notes payable of $5,983 million + Long-term debt of $30,651 million)
• Net Cash Position: $(12,112) million (Cash and cash equivalents + Marketable securities - Total Debt)
• Credit Rating: The Company maintains investment grade credit ratings (specific ratings not disclosed).
• Debt Maturity Profile: Aggregate maturities of long-term debt obligations are $1,749 million in 2025, $1,999 million in 2026, $2,385 million in 2027, $2,275 million in 2028, $1,444 million in 2029, and $22,548 million after 2029.

Cash Flow Generation:

• Operating Cash Flow: $24,266 million
• Free Cash Flow: $19,842 million (Operating Cash Flow of $24,266 million minus Additions to property, plant and equipment of $4,424 million)
• Cash Conversion Metrics: An increase in accounts receivable and inventories of $1,534 million was offset by an increase in accounts payable and accrued liabilities of $1,621 million.

Operational Excellence

Production & Service Model: The Company's subsidiaries operate 64 manufacturing facilities globally, totaling approximately 9.6 million square feet. The Company generally owns its manufacturing facilities, though some are leased, particularly in non-U.S. locations. It also utilizes contract manufacturers. The Company is committed to maintaining all its properties in good operating condition.

Supply Chain Architecture: The Company relies on complex global supply chains and production and distribution processes, which are subject to increasing regulatory requirements. Raw materials essential to the Company's business are generally readily available from multiple sources. Key Suppliers & Partners:

• Wholesalers: Three wholesalers distributing products for both segments represented approximately 20.5%, 15.6%, and 12.3% of total gross revenues in fiscal 2024.
• Manufacturing Partners: The Company engages contract manufacturers.
• Technology Partners: Collaborations with Bayer HealthCare AG (XARELTO), Pharmacyclics LLC, an AbbVie company (IMBRUVICA), Legend Biotech USA Inc. and Legend Biotech Ireland Limited (CARVYKTI), and licensing from Genmab A/S (DARZALEX).

Facility Network:

• Manufacturing: 64 facilities worldwide, with 23 in the U.S. (4 for Innovative Medicine, 19 for MedTech) and 41 internationally (14 for Innovative Medicine, 27 for MedTech).
• Research & Development: R&D activities are a significant part of the Company's business, with substantial investments in discovering, testing, and developing new products.
• Distribution: The Company maintains numerous office and warehouse facilities globally.

Operational Metrics: The filing does not provide specific capacity utilization, efficiency measures, or quality indicators.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Innovative Medicine products are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
• Channel Partners: MedTech products are distributed to wholesalers, hospitals, and retailers.
• Digital Platforms: Not explicitly detailed as a sales channel, but the Company uses its websites (www.jnj.com, www.investor.jnj.com, www.factsabouttalc.com) to communicate with investors and the public.

Customer Portfolio: Enterprise Customers: Products are primarily used in professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Customer Concentration: In 2024, three wholesalers distributing products for both segments represented approximately 20.5%, 15.6%, and 12.3% of the Company's total gross revenues. Geographic Revenue Distribution:

• United States: $50,302 million (56.6% of total revenue)
• Europe: $20,212 million (22.8% of total revenue)
• Western Hemisphere, excluding U.S.: $4,714 million (5.3% of total revenue)
• Asia-Pacific, Africa: $13,593 million (15.3% of total revenue)

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The Company operates in highly competitive global product markets, requiring substantial and continuous investment in research and development. The healthcare landscape is influenced by trends toward cost containment, consolidation among healthcare providers, managed care, and increasing government involvement in healthcare funding and pricing. Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: The Company competes with a wide range of local and global companies. Specific competitors are mentioned in the context of patent litigation and collaborations:

• Generic/Biosimilar Manufacturers: Companies challenging patents for products such as REMICADE, STELARA, XARELTO, INVEGA SUSTENNA, INVEGA TRINZA, SYMTUZA, ERLEADA, SPRAVATO, and INVOKANA.
• Maquet Cardiovascular LLC: Involved in patent litigation with Abiomed.
• C.R. Bard, Inc.: Mentioned in context of polypropylene mesh device litigation.
• Pharmacyclics LLC, an AbbVie company: Co-commercializes IMBRUVICA.
• Bayer HealthCare AG: Co-developed XARELTO.
• Legend Biotech USA Inc. and Legend Biotech Ireland Limited: Collaborates on CARVYKTI.
• Genmab A/S: Licenses DARZALEX.

Emerging Competitive Threats: New market entrants, disruptive technologies (including AI), and increasingly aggressive challenges to the Company's intellectual property rights.

Competitive Response Strategy: The Company's strategy includes substantial investments in R&D, protecting its intellectual property, pursuing strategic acquisitions, collaborations, and licensing agreements, and continuously introducing new and technologically advanced products.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Healthcare Cost Containment: Pricing pressures from third-party payors (government healthcare programs, private insurance, managed care organizations), consolidation among healthcare providers, and new market entrants.
• Government Pricing Pressure: The Inflation Reduction Act (IRA) authorizes government price negotiation for certain high-spend drugs (XARELTO, STELARA, IMBRUVICA selected), imposes rebates for price increases exceeding inflation, and redesigns Medicare Part D benefits, potentially impacting U.S. Innovative Medicine sales. Litigation challenging the IRA is ongoing.
• Patent Expirations & Biosimilar/Generic Competition: Loss of patent exclusivity (e.g., STELARA, REMICADE) often leads to substantial sales reductions due to generic/biosimilar market entry.
• Technology Disruption: Challenges in innovation, product and process obsolescence due to competitor advances, and risks associated with evolving AI technologies (obsolescence, unintended consequences, new regulations).
• Customer Concentration: Reliance on a few large wholesalers for a significant portion of gross revenues.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Manufacturing Interruptions: Difficulties and delays in internal or third-party manufacturing due to regulatory action, quality deviations, labor disputes/shortages, natural disasters, raw material shortages, political unrest, epidemics/pandemics.
• Supplier Dependency: Reliance on third-party manufacturers and suppliers for raw materials, components, and products, with risks of insufficient capacity, quality issues, or untimely delivery.
• Information Technology Systems: Interruptions and breaches of the Company's or its vendors' IT systems (cybersecurity threats), potentially causing reputational, competitive, operational, or financial harm and regulatory action.

Financial & Regulatory Risks

Market & Financial Risks:

• Foreign Currency Exchange: Fluctuations in non-U.S. currencies relative to the U.S. dollar impact revenues and expenses.
• Inflation and Currency Devaluation: Challenges in maintaining profitability in highly inflationary economies (Argentina, Turkey, Venezuela, Egypt).
• Credit & Liquidity: Potential for increased borrowing costs and reduced access to capital markets if credit ratings are downgraded or financial markets are disrupted. Regulatory & Compliance Risks:
• Increasing Governmental Regulation: Subject to costly and complex U.S. and foreign laws and regulations (e.g., U.S. FDA, EU Medical Devices Regulation, privacy, data localization, cybersecurity, AI), leading to increased compliance costs and enforcement risks.
• Product Efficacy/Safety Concerns: Product withdrawals, recalls, governmental investigations, regulatory action, declining sales, and reputational damage.
• Legal Proceedings: Significant litigation exposure including product liability (talc, ASR Hip, PINNACLE, pelvic meshes, Physiomesh, PROCEED, PROLENE, RISPERDAL, ELMIRON), patent disputes, and government investigations (opioids, anti-competitive behavior, False Claims Act, FCPA).
• Tax Law Changes: Changes in domestic and international tax laws (e.g., OECD Pillar Two Directive) and increased audit scrutiny by tax authorities could negatively impact the effective tax rate and results of operations.

Geopolitical & External Risks

Geopolitical Exposure:

• Global Operations Risks: Financial instability in international economies, sovereign risk, governmental controls, restrictive economic policies, and unstable international governments and legal systems.
• Trade Relations: Potential changes in export/import laws, trade restrictions, tariffs, and drug reimportation legislation impacting raw material prices, supply chains, and product development.
• Global Tensions and War: Adverse effects on business, results of operations, or financial condition due to global tensions and war (e.g., Russia-Ukraine war, Middle East conflict), leading to foreign currency volatility, decreased demand, supply chain challenges, export controls, and sanctions.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Immunology: Treatments for immune-mediated inflammatory diseases.
• Infectious Diseases: Antiretroviral medicines for HIV/AIDS.
• Neuroscience: Treatments for mood disorders, neurodegenerative disorders, schizophrenia, and attention deficit hyperactivity disorder.
• Oncology: Therapies for prostate cancer, hematologic malignancies, lung cancer, and bladder cancer, including CAR-T cell therapy, bispecific antibodies, and next-generation antibody drug conjugates.
• Cardiovascular and Metabolism: Oral anticoagulants, treatments for pulmonary arterial hypertension, electrophysiology products, and heart recovery technologies.
• Investment Level: The Company invested $17.2 billion in R&D in 2024, representing 19.4% of revenue.
• Innovation Pipeline: Focus on discovering, testing, and developing new products, improving existing ones, and ensuring product efficacy and regulatory compliance. New products introduced within the past five years accounted for approximately 25% of 2024 sales. The Company leverages data science, machine learning, and AI.

Intellectual Property Portfolio:

• Patent Strategy: The Company's subsidiaries obtain patent protection on products, product uses, formulations, and manufacturing processes globally. Patents related to DARZALEX (U.S. expiry 2029, Europe 2031/2032) and DARZALEX FASPRO are considered material.
• Licensing Programs: Many products are developed in collaboration with strategic partners or licensed from other companies.
• IP Litigation: The Company faces increasing patent challenges from third parties, including generic and biosimilar manufacturers, seeking to market competing products prior to patent expiration. Significant ongoing litigation includes XARELTO, INVEGA SUSTENNA, INVEGA TRINZA, SYMTUZA, ERLEADA, SPRAVATO, INVOKANA, and Impella.

Technology Partnerships:

• Strategic Alliances: Collaborations with Bayer HealthCare AG (XARELTO), Pharmacyclics LLC, an AbbVie company (IMBRUVICA), Legend Biotech USA Inc. and Legend Biotech Ireland Limited (CARVYKTI), and licensing from Genmab A/S (DARZALEX).

Leadership & Governance

Executive Leadership Team

Regulation

The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation and enforcement. The Company is subject to costly and complex U.S. and foreign laws and governmental regulations, and any adverse regulatory action may materially adversely affect the Company's financial condition and business operations. In the U.S., the pharmaceutical product and medical technology industries have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing, advertising, labeling and safety reporting. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the U.S. FDA) continues to result in increases in the amounts of testing and documentation required for U.S. FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction. Similar trends are also evident in major markets outside of the U.S.

2024 Annual Report3

The medical device regulatory framework and the evolving privacy, data localization, and emerging cyber security laws and regulations around the world are examples of such increased regulation. Within the U.S., an increasing number of U.S. States have enacted comprehensive privacy laws, and federal regulators (e.g., the U.S. FDA, FTC and HHS) continue to stress the intersection of health and privacy as a compliance and enforcement priority. In the EU, multiple directives and laws (including NIS2, EHDS, the Data Act, the Cyber Resilience Act, and the AI Act) are rapidly changing privacy and cybersecurity compliance requirements while introducing new enforcement risks. In addition, China has introduced broad personal information protection and data security regulations, with more anticipated, thereby increasing China’s scrutiny of company compliance and data transfer practices. With other jurisdictions enacting similar privacy laws, local data protection authorities will force greater accountability on the collection, access and use of personal data in the healthcare industry. These laws can also restrict transfers of data across borders, potentially impacting how data-driven health care solutions are developed and deployed globally in a compliant manner. Moreover, as a result of the broad scale release and availability of Artificial Intelligence (AI) technologies such as generative AI, a global trend towards more comprehensive and nuanced regulation to ensure the ethical use, privacy, and security of AI is underway that includes standards for transparency, accountability, and fairness, which will require compliance developments or enhancements.

The regulatory agencies under whose purview the Company operates have administrative powers that may subject it to actions such as product withdrawals, recalls, seizure of products and other civil and criminal sanctions. In some cases, the Company’s subsidiaries may deem it advisable to initiate product recalls regardless of whether it has been required or directed to.

The U.S. FDA and regulatory agencies around the globe are also increasing their enforcement activities. If the U.S. FDA were to conclude that we are not in compliance with applicable laws or regulations, or that any of our pharmaceutical products or medical technologies are ineffective or pose an unreasonable safety risk, the U.S. FDA could ban such products, detain or seize adulterated or misbranded products, order a recall, repair, replacement, or refund of such products, withdraw approval for such products, refuse to grant pending applications for marketing authorization or require certificates of foreign governments for exports, and/or require us to notify health professionals and others that the products present unreasonable risks of substantial harm to the public health. The U.S. FDA may also assess civil or criminal penalties against us, our officers or employees and impose operating restrictions on a company-wide basis, or enjoin and/or restrain certain conduct resulting in violations of applicable law. The U.S. FDA may also recommend prosecution to the U.S. Department of Justice. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future clearances, classifications or approvals, and could result in a substantial modification to our business practices and operations. Equivalent enforcement mechanisms exist in different countries in which we conduct business.

The costs of human healthcare have been and continue to be a subject of study, investigation and regulation by governmental agencies and legislative bodies around the world. In the U.S., attention has been focused by states, regulatory agencies and Congress on prices, profits, overutilization and the quality and costs of healthcare generally. Laws and regulations have been enacted to require adherence to strict compliance standards and prevent fraud and abuse in the healthcare industry. There is increased focus on interactions and financial relationships between healthcare companies and healthcare providers. Various state and federal transparency laws and regulations require disclosures of payments and other transfers of value made to certain healthcare practitioners, including physicians, teaching hospitals, and certain non-physician practitioners. Federal and foreign laws governing international business practices require strict compliance with anti-bribery standards and certain prohibitions with respect to payments to any foreign government official. Payors and Pharmacy Benefit Managers (PBMs) are a potent force in the marketplace, and increased attention is being paid to the impact of PBM practices on healthcare cost and access in the U.S.

Our business has been and continues to be affected by federal and state legislation that alters the pricing, coverage, and reimbursement landscape. At the federal level, in August 2022, President Biden signed into law the Inflation Reduction Act (IRA), which includes provisions that effectively authorize the government to establish prices for certain high-spend single-source drugs and biologics reimbursed by the Medicare program, starting in 2026 for Medicare Part D drugs and 2028 for Medicare Part B drugs. On August 29, 2023, the Centers for Medicare & Medicaid Services (“CMS”) published the first “Selected Drug” list, which includes XARELTO and STELARA as well as IMBRUVICA, which is developed in collaboration and co-commercialized in the U.S. with Pharmacyclics LLC, an AbbVie company. The Selected Drug list also included other medicines targeting disease states that are prevalent in the Medicare population. Although CMS published an explanation for how it determined prices for selected drugs in December 2024, uncertainty remains as to the methodology used to determine these prices. The IRA specifies a ceiling price but not a minimum price for selected drugs and does not require CMS to use a specific framework for determining selected drug prices. In any event, we anticipate that the selected products will be subjected to a government-established price for the Medicare population beginning in 2026.

4

The IRA also contains provisions that impose rebates if certain prices increase at a rate that outpaces the rate of inflation, beginning October 1, 2022, for Medicare Part D drugs and January 1, 2023, for Medicare Part B drugs. Separate IRA provisions redesign the Medicare Part D benefit in various ways, including by shifting a greater portion of costs to manufacturers within certain coverage phases and replacing the Part D coverage gap discount program with a new manufacturer discounting program. Failure to comply with IRA provisions may subject manufacturers to various penalties, including civil monetary penalties.

In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssen’s rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRA’s mandatory pricing scheme. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress. In April 2024, Janssen appealed the district court’s denial of its summary judgment motion to the Third Circuit.

Additionally, we expect continued scrutiny on drug pricing and government price reporting from Congress, agencies, and other bodies at the federal and state levels, which may result in additional regulations or other mechanisms to increase pricing transparency and controls.

There are a number of additional bills pending in Congress and healthcare reform proposals at the state level that would affect drug pricing, including in the Medicare and Medicaid programs. This changing legal landscape has both positive and negative impacts on the U.S. healthcare industry with much remaining uncertain as to how various provisions of federal and state law, and potential modification or repeal of these laws, will ultimately affect the industry. The IRA and any other federal or state legislative change could affect the pricing and market conditions for our products.

In addition, business practices in the healthcare industry have come under increased scrutiny, particularly in the U.S., by government agencies and state attorneys general, and resulting investigations and prosecutions carry the risk of significant civil and criminal penalties. Of note is the increased enforcement activity by data protection authorities in various jurisdictions, particularly in the European Union, where significant fines have been levied on companies for data breaches, violations of privacy requirements, and unlawful cross-border data transfers. In the U.S., the Federal Trade Commission has stepped up enforcement of data privacy with several significant settlements (including settlements concerning the downstream sharing of personal information and use and disclosure of personal health data) and there have been a material increase in class-action lawsuits linked to the collection and use of biometric data and use of tracking technologies.

Further, the Company relies on global supply chains, and production and distribution processes, that are complex, and subject to increasing regulatory requirements that may affect sourcing, supply and pricing of materials used in the Company's products. These processes also are subject to complex and lengthy regulatory approvals.

2024 Annual Report5

Employees and human capital management

As of December 29, 2024 and December 31, 2023 the number of employees was approximately:

| | | | 2024 | | | 2023 | | Employees(1) | | 139,800 | | | 134,400 | | | Full-time equivalent (FTE) positions(2) | | 138,100 | | | 131,900 | |

(1) “Employee” is defined as an individual working full-time or part-time, excluding fixed term employees, interns and co-op employees. Employee data may not include full population from more recently acquired companies and individuals on long-term disability are excluded. Contingent workers, contractors and subcontractors are also excluded. Shockwave has been included in the fiscal 2024 headcount in the above table.

(2) FTE represents the total number of full-time equivalent positions and does not reflect the total number of individual employees as some work part-time.

Employees by region (in percentages)

Strategy

The Company believes that its employees are critical to its continued success and are an essential element of its long-term strategy. Management is responsible for ensuring that its policies and processes reflect and reinforce the Company's desired corporate culture, including policies and processes related to strategy, risk management, and ethics and compliance. The Company’s human capital management strategy is built on three fundamental focus areas:

•

Attracting and recruiting top talent

•

Developing and retaining top talent

•

Empowering and inspiring talent

Underpinning these focus areas are ongoing efforts to cultivate and foster a culture built on innovation, health, well-being and safety, inclusion and belonging where the Company's employees are encouraged to succeed both professionally and personally while helping the Company achieve its business goals.

Culture and employee engagement

At Johnson & Johnson, employees are guided by Our Credo, which sets forth the Company's responsibilities to patients, consumers, customers, healthcare professionals, employees, communities and shareholders. Employees worldwide must adhere to the Company’s Code of Business Conduct, which sets fundamental requirements and serves as a foundation for the Company policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors in every market where it operates. The Company conducts global surveys that offer its employees the ability to provide feedback and valuable insight to help address potential human resources risks and identify opportunities to improve. In 2024, 94% of global employees across 73 countries participated in Our Credo Survey which was offered in 36 languages.

6

Growth and development

To lead in the changing healthcare landscape, it is crucial that the Company continue to attract and retain top talent. In 2024, the Company's voluntary turnover rate was 6.3%. The Company believes that its employees must be equipped with the right knowledge and skills and be provided with opportunities to grow and develop in their careers. Accordingly, professional development programs and educational resources are available to all employees. The Company's objective is to foster a learning culture that helps shape each person’s unique career path while creating a robust pipeline of talent to deliver on the Company’s long-term strategies. In furtherance of this objective, the Company deploys a global approach to ensure development is for everyone, regardless of where they are on their career journey. To prioritize learning, the Company recently held Johnson & Johnson's second Global Learning Day. Employees were encouraged to set aside a full day to explore skill-building courses on J&J Learn, the new state-of-the-art learning platform.

Our workforce

As stated in Our Credo, we are responsible to our employees who work with us throughout the world. The Company is committed to cultivating, fostering and advancing an inclusive, credo-based work environment for employees that recognizes and rewards based on merit. The Company is dedicated to the values in Our Credo and strives to meet the needs of its employees and stakeholders through compliance with law and the following evidence based strategies:

• Sustain a global workforce of individuals with many different backgrounds, abilities, cultures and perspectives

• Maintain a work environment where each person’s dignity is respected and they have an opportunity to advance based on their merit

• Drive innovation and growth with our business to serve markets around the world

Our approach with respect to our workforce is guided by applicable laws, internal and external insights, global best practices and employee feedback.

Compensation and benefits

As part of the Company's total rewards philosophy, the Company offers competitive compensation and benefits to attract and retain top talent. The Company is committed to fair treatment in its compensation and benefits for employees at all levels. The Company observes legal minimum wage provisions and exceeds them where possible. The Company's total rewards offerings include an array of programs to support its employees' well-being, including annual performance incentive opportunities, pension and retirement savings programs, health and welfare benefits, paid time off, leave programs, flexible work schedules and employee assistance programs.

Health, wellness and safety

The Company’s investment in employee health, well-being and safety is built on its conviction that advancing health for humanity starts with advancing the health of its employees. With the right awareness, focus, practices and tools, the Company works to ensure that all its employees around the world, as well as contingent workers, contractors and visitors to the Company's sites, can work safely. The Company has continuously expanded health and well-being programs throughout the Company and across the globe, incorporating new thinking and technologies to keep its offerings best-in-class and to help employees achieve their personal health goals. The programs and practices the Company provides—physical, mental, emotional and financial—help promote holistic employee health. The Company continues to address our employees needs through J&J Flex, a hybrid model that empowers the Company’s office-based employees to find a balance of in-person and remote work, while preserving the Company's culture and need for face-to-face engagement and leadership.

2024 Annual Report7

Available information

The Company’s main corporate website address is www.jnj.com . The Company makes its SEC filings available on the Company’s website at www.investor.jnj.com/financials/sec-filings , as soon as reasonably practicable after having been electronically filed or furnished to the SEC. The Company's SEC filings are also available at the SEC’s website at www.sec.gov .

Investors and the public should note that the Company also announces information through its press releases and media statements at www.jnj.com/mediacenter , investor.jnj.com and www.factsabouttalc.com . We use these websites to communicate with investors and the public about our products, litigation and other matters. It is possible that the information we post to these websites could be deemed to be material information. Therefore, we encourage investors and others interested in the Company to review the information posted to these websites in conjunction with www.jnj.com , the Company's SEC filings, press releases, public conference calls and webcasts.

In addition, the Restated Certificate of Incorporation, as amended, Amended and Restated By-Laws, the written charters of the Audit Committee, the Compensation & Benefits Committee, the Nominating & Corporate Governance Committee, the Regulatory Compliance & Sustainability Committee, and the Science & Technology Committee of the Board of Directors, and the Company’s Principles of Corporate Governance, Code of Business Conduct (for employees), Code of Business Conduct & Ethics for Members of the Board of Directors and Executive Officers, and other corporate governance materials are available on the Company's website at www.investor.jnj.com/governance/corporate-governance-overview and will be provided without charge to any shareholder submitting a written request, as provided above. The information on www.jnj.com , investor.jnj.com and www.factsabouttalc.com is not, and will not be deemed, a part of this Report or incorporated into any other filings the Company makes with the SEC.

8

Item 1A. Risk factors

An investment in the Company’s common stock or debt securities involves risks and uncertainties. The Company seeks to identify, manage and mitigate risks to our business, but uncertainties and risks are difficult to predict and many are outside of the Company’s control and cannot therefore be eliminated. In addition to the other information in this report and the Company’s other filings with the SEC, investors should consider carefully the factors set forth below. Investors should be aware that it is not possible to predict or identify all such factors and that the following is not meant to be a complete discussion of all potential risks or uncertainties. If known or unknown risks or uncertainties materialize, the Company’s business, results of operations or financial condition could be adversely affected, potentially in a material way.

Risks related to our business, industry and operations

The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings.

The Company faces substantial competition in its two operating segments and in all geographic markets. The Company’s businesses compete with companies of all sizes on the basis of cost-effectiveness, technological innovations, intellectual property rights, product performance, real or perceived product advantages, pricing and availability and rate of reimbursement. The Company also competes with other market participants in securing rights to acquisitions, collaborations and licensing agreements with third parties. Competition for rights to product candidates and technologies may result in significant investment and acquisition costs and onerous agreement terms for the Company. Competitors’ development of more effective or less costly products, and/or their ability to secure patent and other intellectual property rights and successfully market products ahead of the Company, could negatively impact sales of the Company’s existing products as well as its ability to bring new products to market despite significant prior investment in the related product development. The Company may also experience operational and financial risk in connection with acquisitions if we are unable to fully identify potential risks and liabilities associated with acquired businesses or products, successfully integrate operations and employees, and successfully identify and realize synergies with existing businesses while containing acquisition-related strain on our management, operations and financial resources.

For the Company’s Innovative Medicine businesses, loss of patent exclusivity for a product often is followed by a substantial reduction in sales as competitors gain regulatory approval for generic, biosimilar and other competing products and enter the market. For the Company’s MedTech businesses, technological innovation, product quality, reputation and customer service are especially important to competitiveness. Development by other companies of new or improved products, processes and technologies could threaten to make the Company’s products or technologies less desirable, less economical or obsolete. The Company’s business and operations will be negatively impacted if we are unable to introduce new products or technological advances that are safe, more effective, more effectively marketed or otherwise outperform those of our competitors.

Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation.

The Company’s manufacturing of products requires the timely delivery of sufficient amounts of complex, high-quality components and materials. The Company’s subsidiaries operate 64 manufacturing facilities as well as sourcing from thousands of suppliers around the world. The Company has in the past, and may in the future, face unanticipated interruptions and delays in manufacturing through its internal or external supply chain. Manufacturing disruptions can occur for many reasons including regulatory action, production quality deviations or safety issues, labor disputes, labor shortages, site-specific incidents (such as fires), natural disasters such as hurricanes and other severe weather events, raw material shortages, lack of available inspectors, political unrest, terrorist attacks and epidemics or pandemics. Such delays and difficulties in manufacturing can result in product shortages, declines in sales and reputational impact as well as significant remediation and related costs associated with addressing the shortage.

The Company relies on third parties to manufacture and supply certain of our products. Any failure by or loss of a third-party manufacturer or supplier could result in delays and increased costs, which may adversely affect our business.

The Company relies on third parties to manufacture and supply certain of our raw materials, component parts and products. We depend on these third-party manufacturers to allocate to us a portion of their manufacturing capacity sufficient to meet our needs, to produce products of acceptable quality and at acceptable manufacturing yields and to deliver those products to us on a timely basis and at acceptable prices. However, we cannot guarantee that these third-party manufacturers will be able to meet our near-term or long-term manufacturing requirements, which could result in lost sales and have an adverse effect on our business.

2024 Annual Report9

Other risks associated with our reliance on third parties to manufacture these products include reliance on the third party for regulatory compliance and quality assurance, misappropriation of the Company’s intellectual property, limited ability to manage our inventory, possible breach of the manufacturing agreement by the third party and the possible termination or nonrenewal of the manufacturing agreement by the third party at a time that is costly or inconvenient for us. Moreover, if any of our third-party manufacturers suffers any damage to facilities, loses benefits under material agreements, experiences power outages, encounters financial difficulties, is unable to secure necessary raw materials from its suppliers or suffers any other reduction in efficiency, the Company may experience significant business disruption. In the event of any such disruption, the Company would need to seek and source other qualified third-party manufacturers, likely resulting in further delays and increased costs which could affect our business adversely.

Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business.

Our industry continues to be challenged by the vulnerability of distribution channels to illegal counterfeiting and the presence of counterfeit products in a growing number of markets and over the Internet. Third parties may illegally distribute and sell counterfeit versions of our products, which do not meet our rigorous manufacturing and testing standards. To distributors and patients, counterfeit products may be visually indistinguishable from the authentic version. Counterfeit medicines pose a risk to patient health and safety because of the conditions under which they are manufactured – often in unregulated, unlicensed, uninspected and unsanitary sites – as well as the lack of regulation of their contents.

The industry’s failure to mitigate the threat of counterfeit medicines could adversely impact our business and reputation by impacting patient confidence in our authentic products, potentially resulting in lost sales, product recalls, and an increased threat of litigation. In addition, diversion of our products from their authorized market into other channels may result in reduced revenues and negatively affect our profitability.

Global health crises, pandemics, epidemics, or other outbreaks could adversely disrupt or impact certain aspects of the Company’s business, results of operations and financial condition.

We are subject to risks associated with global health crises, epidemics, pandemics and other outbreaks (such incident(s), a health crisis or health crises). The spread of health crises have caused and may cause the Company to modify its business practices, and take further actions as may be required by government authorities or as the Company determines are in the best interests of our patients, customers, employees and business partners under such circumstances. Impacts to the Company have included and may include adverse impacts to results of operations and financial condition, including lower sales and reduced customer demand and usage of certain of our products. While the Company has robust business continuity plans in place across our global supply chain network designed to help mitigate the impact of health crises, these efforts may not completely prevent our business from being adversely affected in the event of a health crisis. Health crises could adversely impact the Company’s operations, including, among other things, our manufacturing operations, supply chain, third-party suppliers, sales and marketing, and clinical trial operations. Any of these factors could adversely affect the Company’s business, financial results, and global economic conditions generally.

Risks related to government regulation and legal proceedings

Global sales in the Company’s Innovative Medicine and MedTech segments may be negatively impacted by healthcare reforms and increasing pricing pressures.

Sales of the Company’s Innovative Medicine and MedTech products are significantly affected by reimbursements by third-party payors such as government healthcare programs, private insurance plans and managed care organizations. As part of various efforts to contain healthcare costs, these payors are putting downward pressure on prices at which products will be reimbursed. In the U.S., increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, in part due to continued consolidation among healthcare providers, could result in further pricing pressures. In addition, recent legislation and ongoing political scrutiny on pricing, coverage and reimbursement could result in additional pricing pressures. Specifically, the Inflation Reduction Act of 2022 (IRA) has changed Medicare Part D benefit design and has subjected certain of the Company's products to government-established pricing beginning in 2026 and may subject additional products in the future. Failure to adhere to the government's interpretations of the law pending ongoing litigation may expose the Company to penalties. In addition, change to Medicare Part D could have a negative impact on U.S. Innovative Medicine sales. Further, increased third-party utilization of the 340B Federal Drug Discount Program from expanded interpretations of the statute and program abuse may have a negative impact on the Company's financial performance. Outside the U.S., numerous major markets, including the EU, United Kingdom, Japan and China, have pervasive government involvement in funding healthcare and, in that regard, directly or indirectly impose price controls, limit access to, or reimbursement for, the Company’s products, or reduce the value of its intellectual property protection.

10

We are subject to an increasing number of costly and complex governmental regulations in the countries in which operations are conducted which may materially adversely affect the Company’s financial condition and business operations.

As described in Item 1. Business, the Company is subject to an increasing number of extensive government laws and regulations, investigations and legal action by national, state and local government agencies in the U.S. and other countries in which it operates. For example, changes to the U.S. FDA’s timing or requirements for approval or clearance of our products may have a negative impact on our ability to bring new products to market. New and changing laws, regulations, executive orders and other directives may also impose deadlines on the Company, or its third-party suppliers, manufacturers or other partners and providers, for which there may be insufficient time to implement changes to comply with such new regulations and may result in manufacturing delays or other supply chain constraints. If the Company is unable to identify ways to mitigate these delays or constraints, there may be an adverse effect on sales and access to our products.

The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.

In the ordinary course of business, Johnson & Johnson and its subsidiaries are subject to numerous claims and lawsuits involving various issues such as product liability, patent disputes and claims that their product sales, marketing and pricing practices violate various antitrust, unfair trade practices and/or consumer protection laws. The Company’s more significant legal proceedings are described in Note 19 Legal proceedings under Notes to the Consolidated Financial Statements included in Item 8 of this Report. Litigation, in general, and securities, derivative action, class action and multi-district litigation, in particular, can be expensive and disruptive. Some of these matters may include thousands of plaintiffs, may involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. For example, the Company is a defendant in numerous lawsuits arising out of the use of body powders containing talc, primarily JOHNSON’S Baby Powder. While the Company believes it has substantial defenses in these matters, it is not feasible to predict the ultimate outcome of litigation. The Company has been and could in the future be required to pay significant amounts as a result of settlements or judgments in these matters, potentially in excess of accruals, including matters where the Company could be held jointly and severally liable among other defendants. The resolution of, or increase in accruals for, one or more of these matters in any reporting period could have a material adverse effect on the Company’s results of operations and cash flows for that period. The Company does not purchase third-party product liability insurance; however, the Company utilizes a wholly owned captive insurance company subject to certain limits.

Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.

Product concerns, whether raised internally or by litigants, regulators or consumer advocates, and whether or not based on scientific evidence, can result in safety alerts, product recalls, governmental investigations, regulatory action on the part of the U.S. FDA (or its counterpart in other countries), private claims and lawsuits, payment of fines and settlements, declining sales and reputational damage. These circumstances can also result in damage to brand image, brand equity and consumer trust in the Company’s products. Product recalls have in the past, and could in the future, prompt government investigations and inspections, the shutdown of manufacturing facilities, continued product shortages and related sales declines, significant remediation costs, reputational damage, possible civil penalties and criminal prosecution.

The Company faces significant regulatory scrutiny, which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.

The rapid increase in new government laws and regulations imposes significant compliance costs to the Company and a failure of the Company to timely implement changes to comply with these new laws may expose the Company to investigations, legal actions or penalties. Regulatory issues regarding compliance with current Good Manufacturing Practices (cGMP) (and comparable quality regulations in foreign countries) by manufacturers of drugs and devices can lead to fines and penalties, product recalls, product shortages, interruptions in production, delays in new product approvals and litigation. In addition, the marketing, pricing and sale of the Company’s products are subject to regulation, investigations and legal actions including under the Federal Food, Drug, and Cosmetic Act, the Medicaid Rebate Program, federal and state false claims acts, state unfair trade practices acts and consumer protection laws. Scrutiny of healthcare industry business practices by government agencies and state attorneys general in the U.S., and any resulting investigations and prosecutions, carry risk of significant civil and criminal penalties including, but not limited to, debarment from participation in government healthcare programs. Any such debarment could have a material adverse effect on the Company’s business and results of operations. The most significant current investigations and litigation brought by government agencies are described in Note 19 Legal proceedings—Government proceedings under Notes to the Consolidated Financial Statements included in Item 8 of this Report.

2024 Annual Report11

Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.

Changes in tax laws or regulations around the world, including in the U.S. and as led by the Organization for Economic Cooperation and Development, such as the enactment by certain EU and non-EU countries, and the anticipated enactment by additional countries, of a global minimum tax, could negatively impact the Company’s effective tax rate and results of operations. A change in statutory tax rate or certain international tax provisions in any country would result in the revaluation of the Company’s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Company’s Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to tax laws or regulations may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.

See Note 8 Income taxes under Notes to the Consolidated Financial Statements included in Item 8 of this Report for additional information.

The Company conducts business and files tax returns in numerous countries and is addressing tax audits and disputes with many tax authorities. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. The Company regularly assesses the likely outcomes of its tax audits and disputes to determine the appropriateness of its tax reserves. However, any tax authority could take a position on tax treatment that is contrary to the Company’s expectations, which could result in tax liabilities in excess of reserves.

Risks related to our intellectual property

The Company faces increased challenges to intellectual property rights central to its business.

The Company owns or licenses a significant number of patents and other proprietary rights relating to its products and manufacturing processes. These rights are essential to the Company’s businesses and the inability of the Company to secure and maintain these rights may have a detrimental impact on the Company’s financial results. Public policy, both within and outside the U.S., has become increasingly unfavorable toward intellectual property rights. The Company cannot be certain that it will secure and maintain adequate patent protection for new products and technologies in the United States and other important markets.

Competitors routinely challenge the validity or extent of the Company’s owned or licensed patents and proprietary rights through litigation, interferences, oppositions and other proceedings, such as inter partes review (IPR) proceedings before the United States Patent & Trademark Office (USPTO). These proceedings absorb resources and can be protracted as well as unpredictable. In addition, others may claim the Company has infringed their intellectual property rights, including copyrights, patents, or trademarks, and/or has misappropriated their trade secrets, any of which could result in an injunction and/or the need to pay past damages and future royalties and adversely affect the competitive position and sales of our products.

The Company has faced increasing patent challenges from third parties seeking to manufacture and market generic and biosimilar versions of the Company’s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending its patents against such challenges, or upon the “at-risk” launch by the generic or biosimilar firm of its product, the Company can lose a major portion of revenues for the referenced product in a very short period of time. Current legal proceedings involving the Company’s patents and other intellectual property rights are described in Note 19 Legal proceedings—Intellectual property under Notes to the Consolidated Financial Statements included in Item 8 of this Report.

12

Risks related to product development, regulatory approval and commercialization

Significant challenges or delays in the Company’s innovation, development and implementation of new products, technologies and indications could have an adverse impact on the Company’s long-term success.

The Company’s continued growth and success depends on its ability to innovate and develop new and differentiated products and services that address the evolving healthcare needs of patients, providers and consumers. Development of successful products and technologies is also necessary to offset revenue losses when the Company’s existing products lose market share due to various factors such as competition and loss of patent exclusivity. New products introduced within the past five years accounted for approximately 25% of 2024 sales. The Company cannot be certain when or whether it will be able to develop, license or otherwise acquire companies, products and technologies, whether particular product candidates will be granted regulatory approval, and, if approved, whether the products will be commercially successful.

The Company pursues product development through internal research and development as well as through collaborations, acquisitions, joint ventures and licensing or other arrangements with third parties. In all of these contexts, developing new products, particularly pharmaceutical and biotechnology products and medical devices, requires significant investment of resources over many years. Only a very few biopharmaceutical research and development programs result in commercially viable products. The process depends on many factors including the ability to: discern patients’ and healthcare providers’ future needs; develop promising new compounds, strategies and technologies; achieve successful clinical trial results; secure effective intellectual property protection; obtain regulatory approvals on a timely basis; and, if and when they reach the market, successfully differentiate the Company’s products from competing products and approaches to treatment. Moreover, the development and regulatory approval of new products may be delayed due to limits on federal agency budgets or personnel, including reductions to the U.S. FDA’s budget, employees, and operations, which may lead to slower response times and longer review periods. After approval, new products or enhancements to existing products may not be accepted quickly or significantly in the marketplace due to product and price competition, changes in customer preferences or healthcare purchasing patterns, resistance by healthcare providers or uncertainty over third-party reimbursement. Even following initial regulatory approval, the success of a product can be adversely impacted by safety and efficacy findings in larger real-world patient populations, as well as market entry of competitive products.

The Company leverages the use of data science, machine learning and other forms of AI and emerging technologies across varying parts of its business and operations, and the introduction and incorporation of AI may result in unintended consequences or other new or expanded risks and liabilities. AI technology is continuously evolving, and the AI technologies we develop and adopt may become obsolete earlier than planned. Our investments in these technologies may not result in the benefits we anticipate or enable us to obtain or maintain a competitive advantage. The application of AI in our business is emerging and evolving alongside new laws and regulations that may entail significant costs or ultimately limit our ability to continue the use of these technologies. These technologies also carry inherent risks related to data privacy and security further described below.

Risks related to financial and economic market conditions

The Company faces a variety of financial, economic, legal, social and political risks associated with conducting business internationally.

The Company’s extensive operations and business activity throughout the world are accompanied by certain financial, economic, legal, social and political risks, including those listed below.

Foreign currency exchange : In fiscal 2024, approximately 43% of the Company’s sales occurred outside of the U.S., with approximately 23% in Europe, 5% in the Western Hemisphere, excluding the U.S., and 15% in the Asia-Pacific and Africa region. Changes in non-U.S. currencies relative to the U.S. dollar impact the Company’s revenues and expenses. While the Company uses financial instruments to mitigate the impact of fluctuations in currency exchange rates on its cash flows, unhedged exposures continue to be subject to currency fluctuations. In addition, the weakening or strengthening of the U.S. dollar may result in significant favorable or unfavorable translation effects when the operating results of the Company’s non-U.S. business activity are translated into U.S. dollars.

Inflation and currency devaluation risks : The Company faces challenges in maintaining profitability of operations in economies experiencing high inflation rates. Specifically, the Company has accounted for operations in Argentina, Turkey, Venezuela and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. While the Company strives to maintain profit margins in these areas through cost reduction programs, productivity improvements and periodic price increases, it might experience operating losses as a result of continued inflation.

2024 Annual Report13

Illegal importation of pharmaceutical products : The illegal importation of pharmaceutical products from countries where government price controls or other market dynamics result in lower prices may adversely affect the Company’s sales and profitability in the U.S. and other countries in which the Company operates. With the exception of limited quantities of prescription drugs for personal use, foreign imports of pharmaceutical products are illegal under current U.S. law. However, the volume of illegal imports continues to rise as the ability of patients and other customers to obtain the lower-priced imports has grown significantly.

Anti-bribery and other regulations : The Company is subject to various federal and foreign laws that govern its international business practices with respect to payments to government officials. Those laws include the U.S. Foreign Corrupt Practices Act (FCPA), which prohibits U.S. publicly traded companies from promising, offering, or giving anything of value to foreign officials with the corrupt intent of influencing the foreign official for the purpose of helping the Company obtain or retain business or gain any improper advantage. The Company’s business is heavily regulated and therefore involves significant interaction with foreign officials. Also, in many countries outside the U.S., the healthcare providers who prescribe human pharmaceuticals are employed by the government and the purchasers of human pharmaceuticals are government entities; therefore, the Company’s interactions with these prescribers and purchasers are subject to regulation under the FCPA. In addition to the U.S. application and enforcement of the FCPA, various jurisdictions in which the Company operates have laws and regulations, including the U.K. Bribery Act 2010, aimed at preventing and penalizing corrupt and anticompetitive behavior. Enforcement activities under these laws could subject the Company to additional administrative and legal proceedings and actions, which could include claims for civil penalties, criminal sanctions, and administrative remedies, including exclusion from healthcare programs.

Other financial, economic, legal, social and political risks . Other risks inherent in conducting business globally include:

• local and regional economic environments and policies in the markets that we serve, including interest rates, monetary policy, inflation, economic growth, recession, commodity prices, and currency controls or other limitations on the ability to expatriate cash;

• protective economic policies taken by governments, such as trade protection measures, increased antitrust reporting requirements and enforcement activity, and import/export licensing requirements;

• compliance with local regulations and laws including, in some countries, regulatory requirements restricting the Company’s ability to manufacture or sell its products in the relevant market;

• diminished protection of intellectual property and contractual rights in certain jurisdictions;

• potential nationalization or expropriation of the Company’s foreign assets;

• political or social upheavals, economic instability, repression, or human rights issues; and

• geopolitical events, including natural disasters, disruptions to markets due to war, armed conflict, terrorism, epidemics or pandemics.

Due to the international nature of the Company's business, geopolitical or economic changes or events, including global tensions and war, could adversely affect our business, results of operations or financial condition.

As described above, the Company has extensive operations and business activity throughout the world. Global tensions, conflict and/or war among any of the countries in which we conduct business or distribute our products may result in foreign currency volatility, decreased demand for our products in affected countries, and challenges to our global supply chain related to increased costs of materials and other inputs for our products and suppliers. Most recently, we have experienced, and expect to continue to experience, impacts to the Company's business resulting from the Russia-Ukraine war, rising conflict in the Middle East as well as increasing tensions between the U.S. and China. In response to heightened conflict, such as the Russia-Ukraine war, governments may impose export controls and broad financial and economic sanctions. Our business and operations may be further impacted by the imposition of tariffs, trade protection measures or other policies adopted by any country that favor domestic companies and technologies over foreign competitors. Additional sanctions or other measures may be imposed by the global community, including but not limited to limitations on our ability to file, prosecute and maintain patents, trademarks and other intellectual property rights. Furthermore, in some countries, such as in Russia, action may be taken that allows companies and individuals to exploit inventions owned by patent holders from the United States and many other countries without consent or compensation and we may not be able to prevent third parties from practicing the Company's inventions in Russia or from selling or importing products in and into Russia. In addition, the U.S. government recently announced tariffs on products manufactured in several jurisdictions, including China, Mexico and Canada, and has

14

made announcements regarding the potential imposition of tariffs on other jurisdictions. While certain of the announced tariffs have been delayed, the U.S. government may in the future pause, reimpose or increase tariffs, and countries subject to such tariffs have and in the future may impose reciprocal tariffs or other restrictive trade measures in response. Any of these actions could increase uncertainties and associated risks relating to the Company’s global operations.

Weak financial performance, failure to maintain a satisfactory credit rating or disruptions in the financial markets could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.

We currently maintain investment grade credit ratings with Moody’s Investors Service and Standard & Poor’s Ratings Services. Rating agencies routinely evaluate us, and their ratings of our long-term and short-term debt are based on a number of factors. Any downgrade of our credit ratings by a credit rating agency, whether as a result of our actions or factors which are beyond our control, can increase the cost of borrowing under any indebtedness we may incur, reduce market capacity for our commercial paper or require the posting of additional collateral under our derivative contracts. There can be no assurance that we will be able to maintain our credit ratings, and any additional actual or anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade, may have a negative impact on our liquidity, capital position and access to capital markets.

Other risks

Our business depends on our ability to recruit and retain talented and highly skilled employees.

Our continued growth requires us to recruit and retain talented employees representing many different backgrounds, experiences, and skill sets. The market for highly skilled workers and leaders in our industry is extremely competitive and our ability to compete depends on our ability to hire, develop and motivate highly skilled personnel in all areas of our organization. Maintaining our brand and reputation, as well as a credo-based work environment enables us to attract top talent. If we are less successful in our recruiting efforts, or if we cannot retain highly skilled workers and key leaders, our ability to develop and deliver successful products and services may be adversely affected. In addition, effective succession planning is important to our long-term success. Any unsuccessful implementation of our succession plans or failure to ensure effective transfer of knowledge and smooth transitions involving key employees could adversely affect our business, financial condition, or results of operations.

Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.

Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere could present risks to our operations, including an adverse impact on global temperatures, weather patterns and the frequency and severity of extreme weather and natural disasters. Natural disasters and extreme weather conditions, such as a hurricane, tornado, earthquake, wildfire or flooding, may pose physical risks to our facilities and disrupt the operation of our supply chain. The impacts of the changing climate on water resources may result in water scarcity, limiting our ability to access sufficient high-quality water in certain locations, which may increase operational costs.

Concern over climate change may also result in new or additional legal or regulatory requirements designed to reduce greenhouse gas emissions and/or mitigate the effects of climate change on the environment. If such laws or regulations are more stringent than current legal or regulatory obligations, we may experience disruption in, or an increase in the costs associated with sourcing, manufacturing and distribution of our products, which may adversely affect our business, results of operations or financial condition. Further, the impacts of climate change have an influence on customer preferences, and failure to provide climate-friendly products could potentially result in loss of market share.

An information security incident, including a cybersecurity breach, could have a negative impact on the Company’s business or reputation.

To meet business objectives, the Company relies on both internal information technology (IT) systems and networks, and those of third parties and their vendors, to process and store sensitive data (including confidential research, business plans, financial information, intellectual property, and personal data that may be subject to legal protection) to ensure the continuity of the Company’s supply chain and operations, and as part of many of the products we deliver to customers. The extensive range of information security and cybersecurity threats, which affect companies globally, pose a persistent risk to the security and availability of these systems and networks, including to customer products that are connected to or rely on such systems and networks, and the confidentiality, integrity, and availability of the Company’s sensitive data. The Company assesses these threats, responds to attacks and breaches that it has experienced, and makes investments to increase internal protection, detection, and response capabilities, as well as ensure the Company’s third-party providers have required capabilities and

2024 Annual Report15

controls, to address this risk. Because of the frequently changing attack techniques, along with the increased volume and sophistication of the attacks, there is the potential for the Company to be adversely impacted. This impact could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action. Also, increasing use of AI could increase these risks. The Company maintains cybersecurity insurance in the event of an information security or cyber incident; however, the coverage may not be sufficient to cover all financial, legal, business or reputational losses.

As a result of increased global tensions, the Company expects there will continue to be, an increased risk of information security or cybersecurity incidents, including cyberattacks perpetrated by adversaries of countries where the Company maintains operations. Given the potential sophistication of these attacks, the Company may not be able to address the threat of information security or cybersecurity incidents proactively or implement adequate preventative measures and we may not be able to detect and address any such disruption or security breach promptly, or at all, which could adversely affect customers that use our products, our business, results of operations or financial condition. Moreover, these threats could also impact our third-party partners resulting in compromise of the Company's IT systems, networks and data which could negatively affect the Company.

A breach of privacy laws or unauthorized access, loss or misuse of personal data could have a negative impact on the Company’s business or reputation.

The Company is subject to privacy and data protection laws and regulations across the globe that impose broad compliance obligations on the collection, possession, use, storage, access, disclosure, transfer, deletion and protection of personal data. Breach of the requirements of these laws and regulations could result in substantial fines, penalties, governmental actions, private right of actions, including class actions, and damage to our reputation and business. New privacy laws are expected globally, together with greater privacy enforcement by governmental authorities globally, particularly on data localization requirements and data transfers including international data flows. The Company has established privacy compliance programs and controls with which our businesses worldwide are required to comply. However, with many technology and data-driven initiatives evolving across the Company, involving multiple vendors and third parties, there are threats that could impact our business operations and research activities, including potential risks of unauthorized access and loss of personal data as well as legislative actions imposing limitations and controls on the use and sharing of personal data as well as on cross border data flows.

16

Item 1B. Unresolved staff comments

Not applicable.

Item 1C. Cybersecurity

Risk management and strategy

The Company has documented cybersecurity policies and standards, assesses risks from cybersecurity threats, and monitors information systems for potential cybersecurity issues. To protect the Company’s information systems from cybersecurity threats, the Company uses various security tools supporting protection, detection, and response capabilities. The Company maintains a cybersecurity incident response plan to help ensure a timely, consistent response to actual or attempted cybersecurity incidents impacting the Company.

The Company also identifies and assesses third-party risks within the enterprise, and through the Company's use of third-party service providers, across a range of areas including data security and supply chain through a structured third-party risk management program.

The Company maintains a formal information security training program for all employees that includes training on matters such as phishing and email security best practices. Employees are also required to complete mandatory training on data privacy.

To evaluate and enhance its cybersecurity program, the Company periodically utilizes third-party experts to undertake maturity assessments of the Company’s information security program.

To date, the Company is not aware of any cybersecurity incident that has had or is reasonably likely to have a material impact on the Company’s business or operations; however, because of the frequently changing attack techniques, along with the increased volume and sophistication of the attacks, there is the potential for the Company to be adversely impacted.This impact could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action. Refer to the risk factor captioned An information security incident, including a cybersecurity breach, could have a negative impact to the Company’s business or reputation in Part I, Item 1A. Risk factors for additional description of cybersecurity risks and potential related impacts on the Company.

Governance - management’s responsibility

The Company takes a risk-based approach to cybersecurity and has implemented cybersecurity controls designed to address cybersecurity threats and risks. The Chief Information Officer (CIO), who is a member of the Company’s Executive Committee, and the Chief Information Security Officer (CISO)are responsible for assessing and managing cybersecurity risks, including security incident detection, response, and recovery.

The Company’s CISO, in coordination with the CIO, is responsible for leading the Company’s cybersecurity program and management of cybersecurity risk. The current CISO has over twenty-five years of experience in information security, and his background includes technical experience, strategy and architecture focused roles, cyber and threat experience, and various leadership roles.

Governance - board oversight

The Company’s Board of Directorsoversees the overall risk management process, including cybersecurity risks, directly and through its committees. The Regulatory Compliance & Sustainability Committee (RCSC) of the board is primarily responsible for oversight of risk from cybersecurity threats and oversees compliance with applicable laws, regulations and Company policies related to, among others, privacy and cybersecurity.

RCSC meetings include discussions of specific risk areas throughout the year including, among others, those relating to cybersecurity. The CISO provides quarterly updates each year to RCSC on cybersecurity matters. These reports include an overview of the cybersecurity threat landscape, key cybersecurity initiatives to improve the Company’s risk posture, changes in the legal and regulatory landscape relative to cybersecurity, and overviews of certain cybersecurity incidents that have occurred within the Company and within the industry.

2024 Annual Report17

Item 2. Properties

The Company's subsidiaries operate 64 manufacturing facilities occupying approximately 9.6 million square feet of floor space. The manufacturing facilities are used by the industry segments of the Company’s business approximately as follows:

| Segment | | Square Feet (in thousands) | | Innovative Medicine | | 4,696 | | MedTech | | 4,911 | | Worldwide Total | | 9,607 |

Within the U.S., four facilities are used by the Innovative Medicine segment and 19 by the MedTech segment. Outside of the U.S., 14 facilities are used by the Innovative Medicine segment and 27 by the MedTech segment.

The locations of the manufacturing facilities by major geographic areas of the world are as follows:

| Geographic Area | | Number of Facilities | | Square Feet (in thousands) | | United States | | 23 | | 2,892 | | Europe | | 21 | | 4,521 | | Western Hemisphere, excluding U.S. | | 7 | | 898 | | Africa, Asia and Pacific | | 13 | | 1,296 | | Worldwide Total | | 64 | | 9,607 |

In addition to the manufacturing facilities discussed above, the Company maintains numerous office and warehouse facilities throughout the world.

The Company's subsidiaries generally seek to own, rather than lease, their manufacturing facilities, although some, principally in non-U.S. locations, are leased. Office and warehouse facilities are often leased. The Company also engages contract manufacturers.

The Company is committed to maintaining all of its properties in good operating condition.

Segment information on additions to property, plant and equipment is contained in Note 17 Segments of business and geographic areas of the Notes to Consolidated Financial Statements included in Item 8 of this Report.

Item 3. Legal proceedings

The information called for by this item is incorporated herein by reference to the information set forth in Note 19 Legal proceedings of the Notes to Consolidated Financial Statements included in Item 8 of this Report.

Item 4. Mine safety disclosures

Not applicable.

18

Executive officers of the registrant

Listed below are the executive officers of the Company. There are no family relationships between any of the executive officers, and there is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was selected. At the annual meeting of the Board of Directors, the executive officers are elected by the Board to hold office for one year and until their respective successors are elected and qualified, or until earlier resignation or removal.

| Vanessa Broadhurst, 56
Member, Executive Committee; Executive Vice President, Global Corporate Affairs
Ms. V. Broadhurst was named Executive Vice President, Global Corporate Affairs and appointed to the Executive Committee in 2022. Ms. Broadhurst rejoined the Company in 2017 and was appointed Company Group Chairman, Global Commercial Strategy Organization in 2018. From 2013 to 2017, she held General Manager roles at Amgen in Inflammation & Cardiovascular, and Cardiovascular & Bone. Prior to her roles at Amgen, she served in various leadership roles at the Company from 2005-2013. | | Joaquin Duato, 62
Chairman of the Board; Chief Executive Officer
Mr. J. Duato became Chairman of the Board of Directors in 2023 subsequent to his appointments as Chief Executive Officer and Director in 2022. Mr. Duato was appointed to the Executive Committee in 2016 when he was named Executive Vice President, Worldwide Chairman, Pharmaceuticals and subsequently served as Vice Chairman of the Executive Committee. Mr. Duato first joined the Company in 1989 with Janssen-Farmaceutica S.A. (Spain), a subsidiary of the Company, and held executive positions of increasing responsibility in all business sectors and across multiple geographies and functions. | | Elizabeth Forminard, 54
Member, Executive Committee; Executive Vice President, Chief Legal Officer
Ms. E. Forminard was appointed Executive Vice President, Chief Legal Officer and a member of the Executive Committee in 2022. Ms. Forminard joined the Company in 2006, serving in roles of increasing responsibility including General Counsel Medical Devices & Diagnostics, General Counsel Consumer Group & Supply Chain, Worldwide Vice President Corporate Governance, and in her immediate past role as General Counsel Pharmaceuticals. | | Kristen Mulholland, 58
Member, Executive Committee; Executive Vice President, Chief Human Resources Officer
Ms. K. Mulholland was appointed Executive Vice President, Chief Human Resources Officer and appointed to the Executive Committee in 2024. She joined the company in 2005 and has held HR leadership positions across the full breadth of the company including MedTech, Innovative Medicines, our Corporate Functions and Corporate HR Services including Performance and Development and most recently, Global Total Rewards. | | John C. Reed, M.D., Ph.D., 66
Member, Executive Committee; Executive Vice President, Innovative Medicine, R&D
Dr. J. C. Reed joined the Company in 2023 as Executive Vice President, Innovative Medicine, R&D and a member of the Executive Committee. Prior to joining the Company, Dr. Reed held executive leadership positions at Sanofi (2018-2022) and Roche (2013-2018), serving on their respective executive committees. He also served as CEO of Sanford-Burnham Medical Research Institute (now Sanford Burnham Prebys) where he established multiple therapeutic area-aligned research centers and platform technology centers. |

2024 Annual Report19

| Tim Schmid, 55
Member, Executive Committee; Executive Vice President, Worldwide Chairman, MedTech
Mr. T. Schmid was appointed Executive Vice President, Worldwide Chairman, MedTech and a member of the Executive Committee in 2023. He joined the Company in 1993 and has served in leadership positions throughout Johnson & Johnson MedTech, including Chief Strategic Customer Officer and President of Ethicon, and most recently served as Company Group Chairman MedTech Asia Pacific from 2018-2023. | | James Swanson, 59
Member, Executive Committee; Executive Vice President, Chief Information Officer
Mr. J. Swanson was appointed Executive Vice President, Chief Information Officer and a member of the Executive Committee in 2022. He rejoined the Company in 2019 as Chief Information Officer of Johnson & Johnson from Bayer Crop Science, where he served as a member of the Executive Leadership Team and as Chief Information Officer and Head of Digital Transformation. From 1996 to 2005, Mr. Swanson held positions of increasing responsibility at the Company, including Project Manager, Director IT, Sr. Director IT and Vice President, Chief Information Officer. | | Jennifer L. Taubert, 61
Member, Executive Committee; Executive Vice President, Worldwide Chairman, Innovative Medicine
Ms. J. L. Taubert was appointed Executive Vice President, Worldwide Chairman, Innovative Medicine (formerly Pharmaceuticals) and a member of the Executive Committee in 2018. She joined the Company in 2005 as Worldwide Vice President and held several executive positions of increasing responsibility in the Pharmaceuticals sector, including Company Group Chairman, North America, and Company Group Chairman, The Americas from 2012-2018. | | Kathryn E. Wengel, 59
Member, Executive Committee; Executive Vice President, Chief Technical Operations & Risk Officer
Ms. K. E. Wengel was appointed Executive Vice President, Chief Technical Operations & Risk Officer in 2023, subsequent to her appointment to the Executive Committee in 2018 when she was named as Executive Vice President, Chief Global Supply Chain Officer. Ms. Wengel first joined the Company in 1988 as Project Engineer and Engineering Supervisor at Janssen, a subsidiary of the Company. During her tenure with the Company, she has held a variety of strategic leadership and executive positions, including in roles within operations, quality, engineering, new products, information technology, and other technical and business functions. | | Joseph J. Wolk, 58
Member, Executive Committee; Executive Vice President, Chief Financial Officer
Mr. J. J. Wolk was appointed Executive Vice President, Chief Financial Officer and a member of the Executive Committee in 2018. He first joined the Company in 1998 as Finance Manager, Business Development for Ortho-McNeil, a subsidiary of the Company. During his tenure at the Company, he has held a variety of senior leadership roles in several segments and functions across the Company's subsidiaries, including Vice President, Finance and Chief Financial Officer of the Janssen Pharmaceutical Companies, and Vice President, Investor Relations. |

20

Part II

Item 5. Market for registrant’s common equity, related stockholder matters and issuer purchases of equity securities

As of February 6, 2025, there were 114,147 record holders of common stock of the Company. Additional information called for by this item is incorporated herein by reference to the following sections of this Report: Note 16 “Common Stock, Stock Option Plans and Stock Compensation Agreements” of the Notes to Consolidated Financial Statements included in Item 8; and Item 12 “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters – Equity Compensation Plan Information.”

Issuer purchases of equity securities

The following table provides information with respect to common stock purchases by the Company during the fiscal fourth quarter of 2024. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company’s compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal fourth quarter.

| Fiscal Period | | Total Number of Shares
Purchased(1) | | | Avg. Price Paid Per Share | | Total Number of Shares (or Units) Purchased as Part
of Publicly Announced
Plans or Programs | | Maximum Number (or Approximate
Dollar Value) of Shares (or Units) that May Yet Be Purchased Under
the Plans or Programs | | September 30, 2024 through October 27, 2024 | | | 621,412 | | $163.13 | | — | | — | | October 28, 2024 through November 24, 2024 | | | 831,866 | | $158.98 | | — | | — | | November 25, 2024 through December 29, 2024 | | | 150,000 | | $152.96 | | — | | — | | Total | | | 1,603,278 | | | | — | | |

(1) During the fiscal fourth quarter of 2024, the Company repurchased an aggregate of 1,603,278 shares of Johnson & Johnson Common Stock in open-market transactions, all of which were purchased as part of a systematic plan to meet the needs of the Company’s compensation programs.

Item 6. Reserved

2024 Annual Report21

Item 7. Management’s discussion and analysis of results of operations and financial condition

Organization and business segments

Description of the company and business segments

Johnson & Johnson and its subsidiaries (the Company) have approximately 138,100 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world with the primary focus on products related to human health and well-being.

The Company is organized into two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on the following therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolism. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Cardiovascular (previously referred to as Interventional Solutions) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.

The Chief Operating Decision Maker (CODM) is the Company's Chief Executive Officer (Principal Executive Officer).The Executive Committee is Johnson & Johnson’s senior leadership team responsible for setting the strategy and priorities of the Company and driving accountability at all levels. Within the strategic parameters provided by the Executive Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.

In all of its product lines, the Company competes with other companies both locally and globally, throughout the world. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, both internally and externally sourced, involving the development and the improvement of new and existing products and processes, is particularly significant. The development of new and innovative products, as well as protecting the underlying intellectual property of the Company's product portfolio, is important to the Company’s success in all areas of its business. The competitive environment requires substantial investments in continuing research.

Management’s objectives

With Our Credo as the foundation, the Company believes health is everything. The Company's strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through the Company's expertise in Innovative Medicine and MedTech, the Company is uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

New products introduced within the past five years accounted for approximately 25% of 2024 sales. In 2024, $17.2 billion was invested in research and development reflecting management’s commitment to create life-enhancing innovations and to create value through partnerships that will profoundly impact of health for humanity.

Our approximately 138,100 employees are critical drivers of the Company’s success. Employees are empowered and inspired to lead with Our Credo and purpose as guides. This allows every employee to use the Company’s reach and size to advance the Company’s purpose, and to also lead with agility and urgency. Leveraging the extensive resources across the enterprise enables the Company to innovate and execute with excellence. This ensures the Company can remain focused on addressing the unmet needs of society every day and invest for an enduring impact, ultimately delivering value to its patients, consumers and healthcare professionals, employees, communities and shareholders.

22

Research &

development

Acquisitions*

(net of cash acquired)

Dividends paid

per share

<div align='center'>* Includes business combinations and asset acquisitions</div>

Results of operations

Analysis of consolidated sales

For discussion on results of operations and financial condition pertaining to the fiscal years 2023 and 2022 see the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, Item 7. Management's discussion and analysis of results of operations and financial condition. Prior periods disclosed herein were recast to reflect the continuing operations of the Company.

In 2024, worldwide sales increased 4.3% to $88.8 billion as compared to an increase of 6.5% in 2023. These sales changes consisted of the following:

| Sales increase/(decrease) due to: | | | 2024 | | | 2023 | | Volume | | 5.9 | % | | 6.8 | % | | Price | | 0.0 | | | 0.6 | | | Currency | | -1.6 | | | -0.9 | | | Total | | 4.3 | % | | 6.5 | % |

The net impact of acquisitions and divestitures on the worldwide sales growth was a positive impact of 0.5% in 2024 and a positive impact of 1.5% in 2023.

Sales by U.S. companies were $50.3 billion in 2024 and $46.4 billion in 2023. This represents increases of 8.3% in 2024 and 10.6% in 2023. In the fiscal 2024, acquisitions and divestitures had a net positive impact of 0.7% on the U.S. operational sales growth. Sales by international companies were $38.5 billion in 2024 and $38.7 billion in 2023. This represents a decrease of 0.5% in 2024 and an increase of 1.9% in 2023. In fiscal 2024, acquisitions and divestitures had a net positive impact of 0.2% on the international operational sales growth. In fiscal 2024, the impact of the Covid-19 Vaccine sales decline on the international operational sales was a negative 2.6%.

The five-year compound annual growth rates for worldwide, U.S. and international sales were 5.4%, 6.8% and 3.8%, respectively. The ten-year compound annual growth rates for worldwide, U.S. and international sales were 4.0%, 5.4% and 2.5%, respectively.

2024 Annual Report23

In 2024, sales by companies in Europe experienced a decline of 1.0% as compared to the prior year, which included an operational decline of 0.6% and a negative currency impact of 0.4%. In fiscal 2024, the net impact of the Covid-19 Vaccine on the European regions change in operational sales was a negative 4.7%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 3.6% as compared to the prior year, which included operational growth of 20.4%, and a negative currency impact of 16.8%. Sales by companies in the Asia-Pacific, Africa region experienced a decline of 1.2% as compared to the prior year, including operational growth of 2.3% offset by a negative currency impact of 3.5%.

In 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately 20.5%, 15.6% and 12.3% of the total gross revenues. In 2023, the Company had three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total gross revenues.

2024 Sales by geographic region (in billions)

2024 Sales by segment (in billions)

<div align='center'>Note: values may have been rounded</div>

Analysis of sales by business segments

Innovative Medicine segment

Innovative Medicine segment sales in 2024 were $57.0 billion, an increase of 4.0% from 2023, which included operational growth of 5.7% and a negative currency impact of 1.7%. U.S. sales were $34.0 billion, an increase of 9.0%. International sales were $23.0 billion, a decrease of 2.5%, which included operational growth of 1.3% offset by a negative currency impact of 3.8%. In 2024, acquisitions and divestitures had a net negative impact of 0.1% on the operational sales growth of the worldwide Innovative Medicine segment. In fiscal 2024, the net impact of the Covid-19 Vaccine on the total Innovative Medicine and International change in operational sales was a negative 1.8% and 4.2%, respectively.

24

Major Innovative Medicine therapeutic area sales:

| (Dollars in Millions) | | 2024 | | 2023 | | | Total Change | | | Operations Change | | | Currency Change | | Total Immunology | | $17,828 | | $18,052 | | (1.2 | %) | | 0.4 | % | | -1.6 | % | | REMICADE | | 1,605 | | 1,839 | | -12.8 | | | -11.4 | | | -1.4 | | | SIMPONI/SIMPONI ARIA | | 2,190 | | 2,197 | | -0.3 | | | 4.5 | | | -4.8 | | | STELARA | | 10,361 | | 10,858 | | -4.6 | | | -3.4 | | | -1.2 | | | TREMFYA | | 3,670 | | 3,147 | | 16.6 | | | 18.1 | | | -1.5 | | | Other Immunology | | 3 | | 11 | | -74.1 | | | -74.1 | | | — | | | Total Infectious Diseases | | 3,396 | | 4,418 | | -23.1 | | | -22.7 | | | -0.4 | | | COVID-19 VACCINE | | 198 | | 1,117 | | -82.4 | | | -82.4 | | | 0.0 | | | EDURANT/rilpivirine | | 1,272 | | 1,150 | | 10.6 | | | 10.6 | | | 0.0 | | | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | | 1,712 | | 1,854 | | -7.7 | | | -7.1 | | | -0.6 | | | Other Infectious Diseases | | 214 | | 297 | | -27.6 | | | -25.0 | | | -2.6 | | | Total Neuroscience | | 7,115 | | 7,140 | | -0.4 | | | 1.3 | | | -1.7 | | | CONCERTA/methylphenidate | | 641 | | 783 | | -18.1 | | | -15.1 | | | -3.0 | | | INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA | | 4,222 | | 4,115 | | 2.6 | | | 3.4 | | | -0.8 | | | SPRAVATO | | 1,077 | | 689 | | 56.4 | | | 56.8 | | | -0.4 | | | Other Neuroscience | | 1,175 | | 1,553 | | -24.3 | | | -20.7 | | | -3.6 | | | Total Oncology | | 20,781 | | 17,661 | | 17.7 | | | 19.8 | | | -2.1 | | | CARVYKTI | | 963 | | 500 | | | 92.7 | | | 92.7 | | | 0.0 | | DARZALEX | | 11,670 | | 9,744 | | 19.8 | | | 22.2 | | | -2.4 | | | ERLEADA | | 2,999 | | 2,387 | | 25.6 | | | 27.3 | | | -1.7 | | | IMBRUVICA | | 3,038 | | 3,264 | | -6.9 | | | -5.2 | | | -1.7 | | | TECVAYLI | | 549 | | 395 | | 38.8 | | | 39.8 | | | -1.0 | | | ZYTIGA /abiraterone acetate | | 631 | | 887 | | -28.8 | | | -25.0 | | | -3.8 | | | Other Oncology | | 931 | | 484 | | | 92.5 | | | 94.3 | | -1.8 | | | Total Pulmonary Hypertension | | 4,282 | | 3,815 | | 12.3 | | | 14.1 | | | -1.8 | | | OPSUMIT | | 2,184 | | 1,973 | | 10.7 | | | 11.9 | | | -1.2 | | | UPTRAVI | | 1,817 | | 1,582 | | 14.9 | | | 16.1 | | | -1.2 | | | Other Pulmonary Hypertension | | 281 | | 260 | | 7.9 | | | 18.3 | | | -10.4 | | | Total Cardiovascular / Metabolism / Other | | 3,562 | | 3,671 | | -3.0 | | | -2.6 | | | -0.4 | | | XARELTO | | 2,373 | | 2,365 | | 0.3 | | | 0.3 | | | — | | | Other | | 1,189 | | 1,306 | | -8.9 | | | -7.8 | | | -1.1 | | | Total Innovative Medicine Sales | | $56,964 | | 54,759 | | 4.0 | % | | 5.7 | % | | -1.7 | % |

2024 Annual Report25

Immunology products sales were $17.8 billion in 2024, representing a decrease of 1.2% as compared to the prior year. The decline of STELARA (ustekinumab) sales was driven by share loss primarily due to European biosimilar entrants. Lower sales of REMICADE (infliximab) was due to continued biosimilar competition. The growth of TREMFYA (guselkumab) was due to market growth and share gains.

Sales of STELARA in the United States were approximately $6.7 billion in fiscal 2024. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. The Company has settled certain litigation under the Biosimilar Price Competition and Innovation Act of 2009. According to patent settlement and license agreements, the Company expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025 which will impact the Company’s sales of STELARA.

Biosimilar versions of REMICADE have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market. Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE.

Infectious disease products sales were $3.4 billion in 2024, a decline of 23.1% as compared to the prior year primarily driven by a decline in COVID-19 vaccine revenue.

Neuroscience products sales were $7.1 billion in 2024, representing a decrease of 0.4% as compared to the prior year primarily driven by a decline in Other Neuroscience. The decline was partially offset by the growth of SPRAVATO (esketamine) driven by the ongoing launch and increased physician and patient demand.

Oncology products achieved sales of $20.8 billion in 2024, representing an increase of 17.7% as compared to the prior year. Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth. Growth of ERLEADA (apalutamide) was primarily due to continued share gains and market growth. Sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains, capacity expansion and manufacturing efficiencies. Additionally, sales from the ongoing launches of TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs) and RYBREVANT (amivantamab), included in Other Oncology, contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) due to global competitive pressures.

Pulmonary Hypertension products sales were $4.3 billion, representing an increase of 12.3% as compared to the prior year. Sales growth of both OPSUMIT (macitentan) and UPTRAVI (selexipag) was driven by market growth and share gains. Growth in Other Pulmonary Hypertension was driven by OPSYNVI (macitentan/tadalafil).

Cardiovascular/Metabolism/Other products sales were $3.6 billion, a decline of 3.0% as compared to the prior year driven by declines in Other.

The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Company’s drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities.

26

During 2024, the Company advanced its pipeline with several regulatory submissions and approvals for new drugs and additional indications for existing drugs as follows:

| Product Name
(Chemical Name) | | Indication | | US
Approval | | EU
Approval | | US
Filing | | EU
Filing | | BALVERSA (erdafitinib) | | Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations (THOR) | | • | | • | | | | | | CARVYKTI (ciltacabtagene autoleucel) | | Treatment for Relapsed and Refactor multiple myeloma with 1-3 PL (CARTITUDE-4) | | • | | • | | | | | | DARZALEX (daratumumab) | | Treatment for frontline multiple myeloma transplant eligible (PERSEUS) | | • | | • | | | | | | DARZALEX (daratumumab) | | Treatment for frontline multiple myeloma transplant ineligible (CEPHEUS) | | | | | | • | | • | | DARZALEX (daratumumab) | | Treatment as subcutaneous monotherapy for high-risk smoldering multiple myeloma (AQUILA) | | | | | | • | | • | | EDURANT (rilpivirine) | | Treatment for pediatric patients (2-12 years old) with HIV | | • | | • | | | | | | IMBRUVICA (ibrutinib) | | Treatment for frontline MCL (Triangle) | | | | | | | | • | | nipocalimab | | Treatment for Generalized Myasthenia Gravis | | | | | | • | | • | | OPSUMIT (macitentan) | | Treatment for pediatric pulmonary arterial hypertension (TOMORROW) | | | | • | | • | | | | OPSYNVI (macitentan/tadalafil STCT) | | Treatment for pulmonary arterial hypertension | | • | | • | | | | | | REKAMBYS | | Treatment for Adolescents HIV | | | | | | | | • | | RYBREVANT (amivantamab) | | In Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Mutations (PAPILLON) | | • | | • | | | | | | RYBREVANT (amivantamab) | | Treatment for subcutaneous (PALOMA-3) | | | | | | • | | • | | RYBREVANT / LAZCLUZE | | Treatment for Non-Small Cell Lung Cancer (MARIPOSA) | | • | | • | | | | | | RYBREVANT | | Treatment for Non-Small Cell Lung Cancer 2L (MARIPOSA-2) | | • | | • | | | | | | SIMPONI (golimumab) | | Treatment of Patients with Pediatric Ulcerative Colitis | | | | | | • | | • | | SPRAVATO (esketamine) monotherapy | | Treatment of Patients with Treatment Resistant Depression (TRD4005) | | | | | | • | | | | STELARA (ustekinumab) | | Treatment of Patients with Pediatric Crohn's Disease | | | | | | | | • | | TREMFYA (guselkumab) | | Treatment of Patients with Ulcerative Colitis (QUASAR) | | • | | | | | | • | | TREMFYA (guselkumab) | | Subcutaneous Induction for treatment of patients with Ulcerative Colitis (ASTRO) | | | | | | • | | | | TREMFYA (guselkumab) | | Subcutaneous Induction for treatment of patients with Crohn's Disease (GRAVITI) | | | | | | • | | • | | TREMFYA (guselkumab) | | Treatment of Patients with Crohn's Disease (GALAXI) | | | | | | • | | • | | TREMFYA (guselkumab) | | Treatment of Patients with Pediatric Psoriasis | | | | | | • | | | | UPTRAVI (selexipag) | | Treatment of Patients with Pediatric Pulmonary Arterial Hypertension (SALTO) | | | | | | | | • |

2024 Annual Report27

MedTech segment

The MedTech segment sales in 2024 were $31.9 billion, an increase of 4.8% from 2023, which included operational growth of 6.2% and a negative currency impact of 1.4%. U.S. sales were $16.3 billion, an increase of 6.9% as compared to the prior year. International sales were $15.5 billion, an increase of 2.6% as compared to the prior year, which included operational growth of 5.4% and a negative currency impact of 2.8%. In 2024, the net impact of acquisitions and divestitures on the MedTech segment worldwide operational sales growth was a positive 1.5% primarily related to the Shockwave acquisition.

Major MedTech franchise sales:

| (Dollars in Millions) | | | 2024 | | | 2023 | | | Total Change | | | Operations Change | | | Currency Change | | Surgery | | $9,845 | | | 10,037 | | | -1.9 | % | | 0.1 | % | | -2.0 | % | | Advanced | | 4,488 | | | 4,671 | | | -3.9 | | | -2.0 | | | -1.9 | | | General | | 5,358 | | | 5,366 | | | -0.2 | | | 2.0 | | | -2.2 | | | Orthopaedics | | 9,158 | | | 8,942 | | | 2.4 | | | 3.0 | | | -0.6 | | | Hips | | 1,638 | | | 1,560 | | | 5.0 | | | 5.6 | | | -0.6 | | | Knees | | 1,545 | | | 1,456 | | | 6.1 | | | 6.5 | | | -0.4 | | | Trauma | | 3,049 | | | 2,979 | | | 2.3 | | | 2.9 | | | -0.6 | | | Spine, Sports & Other | | 2,926 | | | 2,947 | | | -0.7 | | | -0.1 | | | -0.6 | | | Cardiovascular(1) | | 7,707 | | | 6,350 | | | 21.4 | | | 22.8 | | | -1.4 | | | Electrophysiology | | 5,267 | | | 4,688 | | | 12.3 | | | 14.0 | | | -1.7 | | | Abiomed | | 1,496 | | | 1,306 | | | | 14.5 | | | 14.9 | | -0.4 | | | Shockwave(2) | | 564 | | | — | | | | * | | | * | | — | | | Other Cardiovascular | | 380 | | | 356 | | | 6.9 | | | 8.4 | | | -1.5 | | | Vision | | 5,146 | | | 5,072 | | | 1.5 | | | 3.0 | | | -1.5 | | | Contact Lenses/Other | | 3,733 | | | 3,702 | | | 0.8 | | | 2.6 | | | -1.8 | | | Surgical | | 1,413 | | | 1,370 | | | 3.2 | | | 4.3 | | | -1.1 | | | Total MedTech Sales | | $31,857 | | | 30,400 | | | 4.8 | % | | 6.2 | % | | -1.4 | % |

(1) Previously referred to as Interventional Solutions

(2) Acquired on May 31, 2024

• Percentage greater than 100% or not meaningful

The Surgery franchise sales were $9.8 billion in 2024, representing a decrease of 1.9% from 2023. The decline in Advanced Surgery was primarily due to China volume-based procurement across all platforms and competitive pressures in Energy and Endocutters. This was partially offset by the strength of the portfolio and commercial execution in Biosurgery as well as the strength of new products in Endocutters. Growth in General Surgery was primarily driven by technology penetration and benefits from the differentiated Wound Closure portfolio as well as increased procedure volume. This growth was offset by the negative impact of currency and the Acclarent divestiture.

The Orthopaedics franchise sales were $9.2 billion in 2024, representing an increase of 2.4% from 2023. The fiscal 2024 includes a one-time revenue recognition timing change related to certain products across all Orthopaedic platforms in the U.S. which positively impacted the worldwide Orthopaedics franchise growth as well as the negative impact from the near-term revenue disruption related to the previously announced Orthopaedics restructuring. The growth in Hips reflects continued strength of the portfolio primarily in the Anterior approach, and global procedure growth. The growth in Knees was primarily driven by the ATTUNE portfolio, pull through related to the VELYS Robotic assisted solution and global procedure growth. Growth in Trauma was driven by the adoption of recently launched products. The decline in Spine, Sports & Other was primarily driven by competitive pressures and impacts from China volume-based procurement. This was partially offset by growth in the U.S. market.

28

The Cardiovascular franchise, which includes sales from Shockwave Medical (Shockwave) acquired on May 31, 2024, achieved sales of $7.7 billion in 2024, representing an increase of 21.4% from 2023. Electrophysiology growth was driven by global procedure growth, new product performance and commercial execution. This was partially offset by the impacts of volume-based procurement in China and competitive pressures in Pulsed Field Ablation catheters in the U.S. Abiomed sales reflect the strength of all major commercialized regions driven by the continued adoption of Impella 5.5 and Impella RP.

The Vision franchise achieved sales of $5.1 billion in 2024, representing an increase of 1.5% from 2023. Contact Lenses/Other growth was primarily driven by price actions, continued strong performance in the ACUVUE OASYS 1-Day family of products (including recent launches), impacts from a one-time change in contract shipping terms in the U.S. and lapping of prior year impacts of Russian sanctions partially offset by U.S. distributor stocking dynamics. Surgical growth was primarily driven by the continued strength of recent innovations and commercial execution partially offset by China volume-based procurement and competitive pressures in the U.S.

Analysis of consolidated earnings before provision for taxes on income

Consolidated earnings before provision for taxes on income was $16.7 billion and $15.1 billion for the years 2024 and 2023, respectively. As a percent to sales, consolidated earnings before provision for taxes on income was 18.8% and 17.7%, in 2024 and 2023, respectively.

Earnings before provision for taxes

<div align='center'>(Dollars in billions. Percentages in chart are as a percent to total sales)</div>

Cost of products sold and selling, marketing and administrative expenses:

Cost of products sold

Selling, marketing & administrative

<div align='center'>(Dollars in billions. Percentages in chart are as a percent to total sales)</div>

2024 Annual Report29

Cost of products sold:

Cost of products sold decreased as a percent to sales driven by:

• Lower one-time COVID-19 vaccine supply network related exit costs in 2024 ($0 in 2024 versus $0.2 billion 2023) in the Innovative Medicine business

• Prior year restructuring related excess inventory costs in the MedTech business

partially offset by

• The fair value Inventory step-up of $0.4 billion related to the business combination accounting associated with Shockwave

The intangible asset amortization expense included in cost of products sold was $4.5 billion for both fiscal years 2024 and 2023.

Selling, Marketing and Administrative expense:

Selling, Marketing and Administrative Expenses increased as a percent to sales driven by:

• Increased commercial investment in the Innovative Medicine business

partially offset by

• Optimization efforts related to the residual costs associated with the Kenvue separation

Research and Development expense:

Research and development expense by segment of business was as follows:

| | | 2024 | | | | | | 2023 | | | | | | (Dollars in Millions) | | | Amount | | | % of Sales* | | | Amount | | | % of Sales* | | Innovative Medicine | | $13,529 | | | 23.8 | % | | $11,963 | | | 21.8 | % | | MedTech | | 3,703 | | | 11.6 | | | 3,122 | | | 10.3 | | | Total research and development expense | | $17,232 | | | 19.4 | % | | $15,085 | | | 17.7 | % | | Percent increase/(decrease) over the prior year | | 14.2 | % | | | | | 6.7 | % | | | | | *As a percent to segment sales | | | | | | | | | | | | |

Research and development activities represent a significant part of the Company's business. These expenditures relate to the processes of discovering, testing and developing new products, upfront payments and developmental milestones, improving existing products, as well as ensuring product efficacy and regulatory compliance prior to launch. The Company remains committed to investing in research and development with the aim of delivering high quality and innovative products.

Research and Development increased as a percent to sales primarily driven by:

• Acquired in-process research & development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) and pipeline advancement in the Innovative Medicine business

• Acquired in-process research & development expense of $0.5 billion from the V-Wave acquisition in the MedTech business

In-Process Research and Development Impairments (IPR&D): In the fiscal year 2024, the Company recorded a charge of approximately $0.2 billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020. There was also a partial impairment of this asset for $0.2 billion in the fiscal 2023. This asset is now fully impaired.

Other (Income) Expense, Net: Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, investment (income)/loss related to employee benefit programs, gains and losses on divestitures, certain transactional currency gains and losses, acquisition and divestiture related costs, litigation accruals and settlements, as well as royalty income.

30

Other (income) expense, net for the fiscal year 2024 reflected less expense of $1.9 billion as compared to the prior year primarily due to the following:

| (Dollars in Billions)(Income)/Expense | | 2024 | | 2023 | | Change | | Litigation related(1) | | $5.5 | | 6.9 | | -1.4 | | Acquisition, Integration and Divestiture related(2) | | 0.8 | | 0.3 | | 0.5 | | Changes in the fair value of securities(3) | | 0.3 | | 0.6 | | -0.3 | | COVID-19 vaccine manufacturing exit related costs | | 0.1 | | 0.4 | | -0.3 | | Monetization of royalty rights | | -0.3 | | 0.0 | | -0.3 | | Employee benefit plan related | | -0.9 | | -1.4 | | 0.5 | | Other | | -0.8 | | -0.2 | | -0.6 | | Total Other (Income) Expense, Net | | $4.7 | | 6.6 | | -1.9 |

(1) The fiscal years 2024 and 2023 include charges primarily for talc matters (See Note 19 to the Consolidated Financial Statements for more details). The fiscal year 2023 includes favorable intellectual property related litigation settlements of approximately $0.3 billion.

(2) The fiscal year 2024 is primarily related to the acquisition of Shockwave. The fiscal year 2023 is primarily related to the impairment of Ponvory and one-time integration costs related to the acquisition of Abiomed.

(3) The fiscal year 2024 includes the loss of $0.4 billion on the completion of the debt for equity exchange of the retained stake in Kenvue. The fiscal year 2023 includes $0.4 billion related to the unfavorable change in the fair value of the remaining stake in Kenvue and $0.4 billion related to the partial impairment of Idorsia convertible debt and the change in the fair value of the Idorsia equity securities held.

Interest (Income) Expense: Interest income in the fiscal years 2024 and 2023 was $1.3 billion. Interest expense in the fiscal years 2024 and 2023 was $0.8 billion. Cash, cash equivalents and marketable securities totaled $24.5 billion at the end of 2024, and averaged $23.7 billion as compared to the cash, cash equivalents and marketable securities total of $22.9 billion and $22.6 billion average balance in 2023. The total debt balance at the end of 2024 was $36.6 billion with an average debt balance of $33.0 billion as compared to $29.3 billion at the end of 2023 and an average debt balance of $34.5 billion. The higher debt balance was due to the senior unsecured notes issued by the Company in the fiscal second quarter of 2024. The net proceeds from this offering were used to fund the Shockwave acquisition which closed on May 31, 2024 and for general corporate purposes.

Income before tax by segment

Income (loss) before tax by segment of business were as follows:

| | | Income Before Tax | | | | | Segment Sales | | | | | Percent of Segment Sales | | | | | | (Dollars in Millions) | | | 2024 | | 2023 | | | 2024 | | 2023 | | | 2024 | | | 2023 | | Innovative Medicine | | | $18,919 | | 18,246 | | | 56,964 | | 54,759 | | 33.2 | % | | 33.3 | | | MedTech | | | 3,740 | | 4,669 | | | 31,857 | | 30,400 | | 11.7 | | | 15.4 | | | Segment earnings before tax(1) | | | 22,659 | | 22,915 | | | 88,821 | | 85,159 | | 25.5 | | | 26.9 | | | Less: Expenses not allocated to segments(2) | | | 5,972 | | 7,853 | | | | | | | | | | | | | Worldwide income before tax | | | $16,687 | | 15,062 | | | 88,821 | | 85,159 | | 18.8 | % | | 17.7 | |

(1) See Note 17 to the Consolidated Financial Statements for more details.

(2) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. The fiscal years 2024 and 2023 include charges for talc matters of approximately $5.1 billion and $7.0 billion, respectively. The fiscal 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes an approximately $0.4 billion unfavorable change in the fair value of the retained stake in Kenvue.

2024 Annual Report31

Innovative Medicine segment:

In 2024, the Innovative Medicine segment income before tax as a percent to sales was 33.2% versus 33.3% in 2023. The decrease in the income before tax as a percent of sales was primarily driven by the following:

• Acquired in-process research and development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody

• Litigation expense of $0.4 billion in 2024, primarily related to Risperdal Gynecomastia, versus favorable litigation related items of $0.1 billion in 2023

• Increased research and development to advance the pipeline

• Increased commercial investment in selling and marketing expenses

partially offset by

• Monetization of royalty rights of $0.3 billion in 2024

• Lower one-time COVID-19 Vaccine related exit costs of $0.1 billion in 2024 versus $0.7 billion in 2023

• Lower amortization expense of $0.2 billion in 2024 versus 2023

• Restructuring charges of $0.1 billion in 2024 versus $0.5 billion in 2023

• A gain of $0.1 billion in 2024 as compared to a loss of $0.4 billion in 2023 related to changes in the fair value of securities

MedTech segment:

In 2024, the MedTech segment income before tax as a percent to sales was 11.7% versus 15.4% in 2023. The decrease in the income before tax as a percent to sales was primarily driven by the following:

• Acquisition and integration related costs of $1.0 billion in 2024 (primarily related to the Shockwave acquisition) versus $0.2 billion in 2023 related to Abiomed

• Acquired in-process research and development expense of $0.5 billion from the V-Wave acquisition in 2024

• Higher amortization expense of $0.2 billion in 2024 related to Shockwave

partially offset by

• A gain of $0.2 billion related to the Acclarent divestiture in 2024

• Restructuring related charge of $0.2 billion in 2024 versus $0.3 billion in 2023

Restructuring: In the fiscal year 2023, the Company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The pre-tax restructuring charge of approximately $0.1 billion in the fiscal year 2024 was recorded in Restructuring on the Consolidated Statement of Earnings, and included the termination of partnered and non-partnered development program costs, asset impairments and asset divestments. The pre-tax restructuring charge of approximately $0.5 billion in the fiscal year 2023, of which $449 million was recorded in Restructuring and $30 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, and included the termination of partnered and non-partnered program costs and asset impairments. Total project costs of approximately $0.6 billion have been recorded since the restructuring was announced. The program was completed in the fiscal fourth quarter of 2024.

32

In the fiscal year 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $0.2 billion in the fiscal year 2024, of which $132 million was recorded in Restructuring and $35 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, primarily included costs related to market and product exits. The pre-tax restructuring expense of $0.3 billion in the fiscal year 2023, of which $40 million was recorded in Restructuring and $279 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, primarily included inventory and instrument charges related to market and product exits. Total project costs of approximately $0.5 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $0.7 billion - $0.8 billion and is expected to be completed by the end of fiscal year 2025.

See Note 20 to the Consolidated Financial Statements for additional details related to the restructuring programs.

Provision for Taxes on Income: The worldwide effective income tax rate from continuing operations was 15.7% in 2024 and 11.5% in 2023. For discussion related to the fiscal year 2024 provision for taxes refer to Note 8 to the Consolidated Financial Statements.

On December 15, 2022, the European Union (EU) Member States formally adopted the EU’s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. Several EU and non-EU countries have enacted Pillar Two legislation with an initial effective date of January 1, 2024, with other aspects of the law effective in 2025 or later. In the fiscal year 2024, the net impact of Pillar Two legislation was less than 1.0% to the Company’s effective tax rate. While countries continue to enact new provisions or issue new regulations, based on current guidance, the Company expects the net impact of Pillar Two in fiscal year 2025 to be up to 1.0% to the Company’s effective tax rate.

Liquidity and capital resources

Liquidity & cash flows

Cash and cash equivalents were $24.1 billion at the end of 2024 as compared to $21.9 billion at the end of 2023.

The primary sources and uses of cash that contributed to the $2.2 billion increase were:

| (Dollars in billions) | | | | | | $21.9 | | Q4 2023 Cash and cash equivalents balance | | | 24.3 | | cash generated from operating activities | | | -18.6 | | net cash used by investing activities | | | -3.1 | | net cash used by financing activities | | | -0.4 | | effect of exchange rate and rounding | | | $24.1 | | Q4 2024 Cash and cash equivalents balance |

In addition, the Company had $0.4 billion in marketable securities at the end of fiscal year 2024 and $1.1 billion at the end of fiscal year 2023. See Note 1 to the Consolidated Financial Statements for additional details on cash, cash equivalents and marketable securities.

Cash flow from operations of $24.3 billion was the result of:

| (Dollars In billions) | | | | | | $14.1 | | Net Earnings | | | 8.4 | | non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and charges for acquired in-process research and development assets partially offset by net gain on sale of assets/businesses and the deferred tax provision | | | 1.7 | | a decrease in other current and non-current assets | | | 1.6 | | an increase in accounts payable and accrued liabilities | | | -1.5 | | an increase in accounts receivable and inventories | | | $24.3 | | Cash flow from operations |

2024 Annual Report33

Cash flow used for investing activities of $18.6 billion was primarily due to:

| (Dollars in billions) | | | | | | $(4.4) | | additions to property, plant and equipment | | | -15.1 | | acquisitions, net of cash acquired | | | 0.7 | | proceeds from the disposal of assets/businesses, net | | | -1.8 | | acquired in-process research and development assets | | | 0.7 | | net sales of investments | | | 1.5 | | credit support agreements activity, net | | | -0.2 | | other (including capitalized licenses and milestones) | | | $(18.6) | | Net cash used for investing activities |

Cash flow used for financing activities of $3.1 billion was primarily due to:

| (Dollars in billions) | | | | | | $(11.8) | | dividends to shareholders | | | -2.4 | | repurchase of common stock | | | 11.0 | | net proceeds from short and long-term debt | | | 0.8 | | proceeds from stock options exercised/employee withholding tax on stock awards, net | | | 0.3 | | credit support agreements activity, net | | | -1.0 | | settlement of convertible debt acquired from Shockwave | | | $(3.1) | | Net cash used for financing activities |

The following table summarizes cash taxes paid net of refunds:

| (Dollars in Millions) | | 2024 | | 2023 | | 2022 | | U.S. Federal(1) | | $3,815 | | 4,722 | | 2,158 | | U.S. State and Local taxes | | 341 | | 236 | | 216 | | Total U.S. | | $4,156 | | 4,958 | | 2,374 | | Total Foreign | | 2,558 | | 3,616 | | 2,849 | | Total cash taxes paid net of refunds | | $6,714 | | $8,574 | | $5,223 |

(1) Includes TCJA foreign undistributed earnings payments of $2.0 billion in fiscal year 2024, $1.5 billion in fiscal year 2023 and $0.8 billion in fiscal year 2022

As of December 29, 2024, the Company's notes payable and long-term debt was in excess of cash, cash equivalents and marketable securities. As of December 29, 2024, the net debt position was $12.1 billion as compared to the prior year of $6.4 billion. The debt balance at the end of 2024 was $36.6 billion as compared to $29.3 billion in 2023. In the fiscal second quarter of 2024, the Company issued senior unsecured notes for a total of $6.7 billion. For additional details on borrowings, see Note 7 to the Consolidated Financial Statements. The net proceeds from this offering were used to fund the Shockwave acquisition which closed on May 31, 2024, and for general corporate purposes. Considering recent market conditions, the Company has re-evaluated its operating cash flows and liquidity profile and does not foresee any significant incremental risk. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company's remaining balance to be paid on the agreement to settle opioid litigation for approximately $1.5 billion and the approximately $11.6 billion ($13.5 billion nominal) reserve for talc matters (See Note 19 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.

On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the Kenvue Common Stock), at an initial public offering of $22.00 per share for net proceeds of $4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson

34

divested interest was $2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet.

On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1% ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson & Johnson acquiring 190,955,436 shares of the Company’s common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock. The $31.4 billion of Johnson & Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owned 9.5% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $4.3 billion as of August 23, 2023 and $3.9 billion as of December 31, 2023.

Johnson & Johnson divested net assets of $11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $4.3 billion. Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $1.2 billion to record the deconsolidation of Kenvue. This resulted in a gain on the exchange offer of $21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.

On May 15, 2024, the Company issued $3.6 billion aggregate principal amount of commercial paper and received $3.6 billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $0.4 billion recorded in Other (income) expense.

The following table summarizes the Company’s material contractual obligations and their aggregate maturities as of December 29, 2024: To satisfy these obligations, the Company intends to use cash from operations.

| (Dollars in Millions) | | Tax Legislation (TCJA) | | Debt Obligations | | Interest on Debt Obligations | | Total | | 2025 | | $2,536 | | 1,749 | | 1,075 | | 5,360 | | 2026 | | — | | 1,999 | | 1,030 | | 3,029 | | 2027 | | — | | 2,385 | | 1,021 | | 3,406 | | 2028 | | — | | 2,275 | | 977 | | 3,252 | | 2029 | | — | | 1,444 | | 922 | | 2,366 | | After 2029 | | — | | 22,548 | | 8,921 | | 31,469 | | Total | | $2,536 | | 32,400 | | 13,946 | | 48,882 |

For tax matters, see Note 8 to the Consolidated Financial Statements. For the proposed talc settlement payments, see Note 19 to the Consolidated Financial Statements.

2024 Annual Report35

Financing and market risk

The Company uses financial instruments to manage the impact of foreign exchange rate changes on cash flows. Accordingly, the Company enters into forward foreign exchange contracts to protect the value of certain foreign currency assets and liabilities and to hedge future foreign currency transactions primarily related to product costs. Gains or losses on these contracts are offset by the gains or losses on the underlying transactions. A 10% appreciation of the U.S. Dollar from the December 29, 2024 market rates would increase the unrealized value of the Company’s forward contracts by $0.2 billion. Conversely, a 10% depreciation of the U.S. Dollar from the December 29, 2024 market rates would decrease the unrealized value of the Company’s forward contracts by $0.2 billion. In either scenario, the gain or loss on the forward contract would be offset by the gain or loss on the underlying transaction, and therefore, would have no impact on future anticipated earnings and cash flows.

The Company hedges the exposure to fluctuations in currency exchange rates, and the effect on certain assets and liabilities in foreign currency, by entering into currency swap contracts. A 1% change in the spread between U.S. and foreign interest rates on the Company’s interest rate sensitive financial instruments would either increase or decrease the unrealized value of the Company’s swap contracts by approximately $1.5 billion. In either scenario, at maturity, the gain or loss on the swap contract would be offset by the gain or loss on the underlying transaction, and therefore, would have no impact on future anticipated cash flows.

The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The counterparties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counterparty. Management believes the risk of loss is remote. The Company entered into credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. See Note 6 to the Consolidated Financial Statements for additional details on credit support agreements.

The Company invests in both fixed rate and floating rate interest earning securities which carry a degree of interest rate risk. The fair market value of fixed rate securities may be adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than predicted if interest rates fall. A 1% (100 basis points) change in spread on the Company’s interest rate sensitive investments would either increase or decrease the unrealized value of cash equivalents and current marketable securities by less than $8.0 million.

The Company has access to substantial sources of funds at numerous banks worldwide. In June 2024, the Company secured a new 364-day Credit Facility of $10 billion, which expires on June 25, 2025. Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.

Total borrowings at the end of 2024 and 2023 were $36.6 billion and $29.3 billion, respectively. The increase in the borrowings was due to the issuance of new debt in 2024. In 2024, net debt (cash and current marketable securities, net of debt) was $12.1 billion compared to net debt of $6.4 billion in 2023. Total debt represented 34.0% of total capital (shareholders’ equity and total debt) in 2024 and 30.0% of total capital in 2023. Shareholders’ equity per share at the end of 2024 was $29.70 compared to $28.57 at year-end 2023.

A summary of borrowings can be found in Note 7 to the Consolidated Financial Statements.

Dividends

The Company increased its dividend in 2024 for the 62 nd consecutive year. Cash dividends paid were $4.91 per share in 2024 and $4.70 per share in 2023.

On January 2, 2025, the Board of Directors declared a regular cash dividend of $1.24 per share, payable on March 4, 2025 to shareholders of record as of February 18, 2025.

36

Other information

Critical accounting policies and estimates

Management’s discussion and analysis of results of operations and financial condition are based on the Company’s consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). The preparation of these financial statements requires that management make estimates and assumptions that affect the amounts reported for revenues, expenses, assets, liabilities and other related disclosures. Actual results may or may not differ from these estimates. The Company believes that the understanding of certain key accounting policies and estimates are essential in achieving more insight into the Company’s operating results and financial condition. These key accounting policies include revenue recognition, income taxes, legal and self-insurance contingencies, valuation of long-lived assets, assumptions used to determine the amounts recorded for pensions and other employee benefit plans and accounting for stock based awards.

Revenue Recognition: The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales.

Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates and discounts are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.

Sales returns are estimated and recorded based on historical sales and returns information. Products that have lost patent exclusivity, or that otherwise exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.

Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Innovative Medicine segment are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during the fiscal years 2024, 2023 and 2022.

Promotional programs, such as product listing allowances are recorded in the same period as related sales and include volume-based sales incentive programs. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in fiscal year 2024 and 2023, respectively, and less than 3.0% of the total revenues in the fiscal year 2022 and are included in sales to customers.

In addition, the Company enters into collaboration arrangements that contain multiple revenue generating activities. Amounts due from collaborative partners for these arrangements are recognized as each activity is performed or delivered, based on the relative selling price. Upfront fees received as part of these arrangements are deferred and recognized over the performance period. See Note 1 to the Consolidated Financial Statements for additional disclosures on collaborations.

Reasonably likely changes to assumptions used to calculate the accruals for rebates, returns and promotions are not anticipated to have a material effect on the financial statements. The Company currently discloses the impact of changes to assumptions in the quarterly or annual filing in which there is a material financial statement impact.

2024 Annual Report37

Below are tables that show the progression of accrued rebates, returns, promotions, reserve for doubtful accounts and reserve for cash discounts by segment of business for the fiscal years ended December 29, 2024 and December 31, 2023.

Innovative Medicine segment

| (Dollars in Millions) | | Balance at Beginning
of Period | | | Accruals | | Payments/
Credits(2) | | | Balance at End of
Period | | | 2024 | | | | | | | | | | | | | Accrued rebates(1) | | | $14,661 | | 52,786 | | | -51,667 | | | 15,780 | | Accrued returns | | | 634 | | 845 | | | -355 | | | 1,124 | | Accrued promotions | | | 6 | | 3 | | | -6 | | | 3 | | Subtotal | | | $15,301 | | 53,634 | | | -52,028 | | | 16,907 | | Reserve for doubtful accounts | | | 33 | | 14 | | | -6 | | | 41 | | Reserve for cash discounts | | | 111 | | 1,493 | | | -1,495 | | | 109 | | Total | | | $15,445 | | 55,141 | | | -53,529 | | | 17,057 | | 2023 | | | | | | | | | | | | | Accrued rebates(1) | | | $12,289 | | 47,523 | | | -45,151 | | | 14,661 | | Accrued returns | | | 649 | | 332 | | | -347 | | | 634 | | Accrued promotions | | | 1 | | 12 | | | -7 | | | 6 | | Subtotal | | | $12,939 | | 47,867 | | | -45,505 | | | 15,301 | | Reserve for doubtful accounts | | | 44 | | 0 | | | -11 | | | 33 | | Reserve for cash discounts | | | 110 | | 1,386 | | | -1,385 | | | 111 | | Total | | | $13,093 | | 49,253 | | | -46,901 | | | 15,445 |

(1) Includes reserve for customer rebates of $187 million at December 29, 2024 and $165 million at December 31, 2023, recorded as a contra asset.

(2) Includes prior period adjustments

38

MedTech segment

| (Dollars in Millions) | | Balance at Beginning of Period | | Accruals | | Payments/ Credits | | Balance at End of Period | | 2024 | | | | | | | | | | Accrued rebates(1) | | $1,455 | | 5,955 | | -5,986 | | 1,424 | | Accrued returns | | 125 | | 543 | | -550 | | 118 | | Accrued promotions | | 25 | | 62 | | -65 | | 22 | | Subtotal | | $1,605 | | 6,560 | | -6,601 | | 1,564 | | Reserve for doubtful accounts | | 133 | | 31 | | -38 | | 126 | | Reserve for cash discounts | | 5 | | 92 | | -91 | | 6 | | Total | | $1,743 | | 6,683 | | -6,730 | | 1,696 | | 2023 | | | | | | | | | | Accrued rebates(1) | | $1,470 | | 6,241 | | -6,256 | | 1,455 | | Accrued returns | | 134 | | 555 | | -564 | | 125 | | Accrued promotions | | 43 | | 74 | | -92 | | 25 | | Subtotal | | $1,647 | | 6,870 | | -6,912 | | 1,605 | | Reserve for doubtful accounts | | 125 | | 33 | | -25 | | 133 | | Reserve for cash discounts | | 9 | | 96 | | -100 | | 5 | | Total | | $1,781 | | 6,999 | | -7,037 | | 1,743 |

(1) Includes reserve for customer rebates of $704 million at December 29, 2024 and $740 million at December 31, 2023, recorded as a contra asset.

Income Taxes: Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities.

The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.

The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.

See Note 1 and Note 8 to the Consolidated Financial Statements for further information regarding income taxes.

Legal and Self Insurance Contingencies: The Company records accruals for various contingencies, including legal proceedings and product liability claims as these arise in the normal course of business. The accruals are based on management’s judgment as to the probability of losses and, where applicable, actuarially determined estimates. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.

The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated.

2024 Annual Report39

See Notes 1 and 19 to the Consolidated Financial Statements for further information regarding product liability and legal proceedings.

Long-Lived and Intangible Assets: The Company assesses changes, both qualitatively and quantitatively, in economic conditions and makes assumptions regarding estimated future cash flows in evaluating the value of the Company’s property, plant and equipment, goodwill and intangible assets. As these assumptions and estimates may change over time, it may or may not be necessary for the Company to record impairment charges.

Employee Benefit Plans: The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. These plans are based on assumptions for the discount rate, expected return on plan assets, mortality rates, expected salary increases, healthcare cost trend rates and attrition rates. See Note 10 to the Consolidated Financial Statements for further details on these rates.

Stock Based Compensation: The Company recognizes compensation expense associated with the issuance of equity instruments to employees for their services. Based on the type of equity instrument, the fair value is estimated on the date of grant using either the Black-Scholes option valuation model or a combination of both the Black-Scholes option valuation model and Monte Carlo valuation model, and is expensed in the financial statements over the service period. The input assumptions used in determining fair value are the expected life, expected volatility, risk-free rate and expected dividend yield. For performance share units, the fair market value is calculated for the two component goals at the date of grant: adjusted operational earnings per share and relative total shareholder return. The fair values for the earnings per share goal of each performance share unit was estimated on the date of grant using the fair market value of the shares at the time of the award, discounted for dividends, which are not paid on the performance share units during the vesting period. The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model. See Note 16 to the Consolidated Financial Statements for additional information.

New accounting pronouncements

Refer to Note 1 to the Consolidated Financial Statements for recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted as of December 29, 2024.

40

Economic and market factors

The Company is aware that its products are used in an environment where, for more than a decade, policymakers, consumers and businesses have expressed concerns about the rising cost of healthcare. In response to these concerns, the Company has a long-standing policy of pricing products responsibly. For the period 2014 - 2024, in the U.S., the weighted average compound annual growth rate of the Company’s net price increases for healthcare products (prescription and over-the-counter drugs, hospital and professional products) was below the U.S. Consumer Price Index (CPI).

The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate. The Company has accounted for operations in Argentina, Venezuela, Turkey and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. This did not have a material impact to the Company's results in the period. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.

In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssen’s rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRA’s mandatory pricing scheme. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress. In April 2024, Janssen appealed the district court’s denial of its summary judgment motion to the Third Circuit.

Russia-Ukraine War

Although the long-term implications of Russia’s invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal year 2024, including accounts receivable or inventory reserves, was not material. As of and for each of the fiscal years ending December 29, 2024 and December 31, 2023, the business of the Company’s Russian subsidiaries represented less than 1% of the Company’s consolidated assets and revenues. The Company does not maintain Ukraine subsidiaries subsequent to the Kenvue separation.

In March of 2022, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia. The Company continues to supply products relied upon by patients for healthcare purposes.

Conflict in the Middle East

Although the long-term implications of the conflict in the Middle East are difficult to predict at this time, the financial impact of the conflict in the fiscal year 2024, including accounts receivable or inventory reserves, was not material. As of and for each of the fiscal years ending December 29, 2024 and December 31, 2023, the business of the Company’s Israel subsidiaries represented 1% of the Company’s consolidated assets and represented less than 1% of revenues.

The Company is exposed to fluctuations in currency exchange rates. A 1% change in the value